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 1 
Abstract 2 
Background 3 
4 
5 
6 
7 
8 
Mood disorders (including major depressive disorder and bipolar disorder) affect 10-
20% of the population. They range from brief, mild episodes to severe, incapacitating 
conditions that markedly impact lives. Despite their diagnostic distinction, multiple 
approaches have shown considerable sharing of risk factors across the mood 
disorders.  
Methods 9 
10 
11 
12 
13 
14 
15 
To clarify their shared molecular genetic basis, and to highlight disorder-specific 
associations, we meta-analysed data from the latest Psychiatric Genomics 
Consortium (PGC) genome-wide association studies of major depression (including 
data from 23andMe) and bipolar disorder, and an additional major depressive 
disorder cohort from UK Biobank (total: 185,285 cases, 439,741 controls; non-
overlapping N = 609,424).  
Results 16 
17 
18 
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Seventy-three loci reached genome-wide significance in the meta-analysis, including 
15 that are novel for mood disorders. More genome-wide significant loci from the 
PGC analysis of major depression than bipolar disorder reached genome-wide 
significance. Genetic correlations revealed that type 2 bipolar disorder correlates 
strongly with recurrent and single episode major depressive disorder. Systems 
biology analyses highlight both similarities and differences between the mood 
disorders, particularly in the mouse brain cell-types implicated by the expression 
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patterns of associated genes. The mood disorders also differ in their genetic 
correlation with educational attainment – positive in bipolar disorder but negative in 
major depressive disorder.  
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Conclusions 4 
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The mood disorders share several genetic associations, and can be combined 
effectively to increase variant discovery. However, we demonstrate several 
differences between these disorders. Analysing subtypes of major depressive 
disorder and bipolar disorder provides evidence for a genetic mood disorders 
spectrum.
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 Mood disorders affect 10-20% of the global population across their lifetime, 
ranging from brief episodes to incapacitating conditions that markedly impact lives 
(1–4). Major depressive disorder and bipolar disorder are the most common forms 
and have been grouped together since the Diagnostic and Statistical Manual of 
Mental Disorders’ third edition (DSM-III) (5). Although given dedicated chapters in 
DSM5, they remain grouped as mood disorders in the International Classification of 
Disorders (ICD11) (6, 7). 
Depressive episodes are common to major depressive disorder and type 2 
bipolar disorder, and are usually present in type 1 bipolar disorder (7). The bipolar 
disorders are distinguished from major depressive disorder by the presence of mania 
in type 1 and hypomania in type 2 (7). However, these distinctions are not absolute – 
some individuals with major depressive disorder develop bipolar disorder, and some 
endorse (hypo)manic symptoms (8–10). Following their first depressive episode, a 
non-remitting individual might develop recurrent major depressive disorder or bipolar 
disorder. Treatment guidelines for these disorders differ (11, 12). Identifying shared 
and distinct genetic associations for major depressive disorder and bipolar disorder 
could aid our understanding of these diagnostic trajectories. 
Twin studies suggest that 35-45% of variance in risk for major depressive 
disorder, and 65-70% for bipolar disorder, is accounted for by additive genetic 
factors (13). These genetic components are partially shared, with a twin genetic 
correlation (rg) of ~65%, and a common variant based rg of 30-35%, derived from 
genome-wide association study (GWAS) results (14–17). Progress has been made 
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in identifying specific genetic variants that underlie genetic risk. Recently, the 
Psychiatric Genomics Consortium (PGC) published a GWAS of bipolar disorder, 
including over 20,000 cases, with 30 genomic loci reaching genome-wide 
significance 
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(16). They also performed a GWAS of major depression, including over 
135,000 individuals with major depressive disorder and other definitions of 
depression, with 44 loci reaching genome-wide significance (15). The PGC GWAS of 
major depression has since been combined with a broad depression GWAS 
(Supplementary Note). 
GWAS have identified statistical associations with major depressive disorder 
and with bipolar disorder individually, but have not explored the genetic relationship 
between these disorders. In addition, both disorders exhibit considerable clinical 
heterogeneity and can be separated into subtypes. For example, the DSM5 includes 
categories for bipolar disorder type 1 and type 2, and for single episode and 
recurrent major depressive disorder (7). We use the PGC analyses of major 
depression and bipolar disorder, along with analyses of formally-defined major 
depressive disorder from UK Biobank, to explore two aims (18, 19). Firstly, we seek 
to identify shared and distinct mood disorder genetics by combining studies of major 
depressive disorder and bipolar disorder. We then explore the genetic relationship of 
mood disorders to traits from the wider GWAS literature. Secondly, we assess 
genetic similarities and differences between subtypes of bipolar disorder (from the 
PGC) and major depressive disorder (from UK Biobank), through comparing genetic 
correlations and polygenic risk scores.  
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Materials and Methods 2 
Participants  3 
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Our primary aim was to combine analyses of bipolar disorder and major 
depression to examine the shared and distinct genetics of these disorders. Full 
descriptions of each study and their composite cohorts are provided in each paper 
(15, 16, 19). Brief descriptions are provided in the Supplementary Methods. 
Summary statistics were derived from participants of Western European ancestries, 
and unless otherwise specified are available (or will be made available) at 
https://www.med.unc.edu/pgc/results-and-downloads. 10 
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Major depression data were drawn from the full cohort (PGC MDD: 135,458 
cases, 344,901 controls) from (15). This included data from 23andMe (20), access to 
which requires a Data Transfer Agreement; consequently, the data analysed here 
differ from the publicly-available summary statistics. Data for bipolar disorder were 
drawn from the discovery analysis previously reported (PGC BD: 20,352 cases, 
31,358 controls), not including replication results (16). 
Secondly, we wished to examine genetic correlations between mood disorder 
subtypes. Summary statistics were available for the primary bipolar disorder 
subtypes, type 1 bipolar disorder (BD1: 14,879 cases, 30,992 controls) and type 2 
bipolar disorder (BD2: 3,421 cases, 22,155 controls), and for schizoaffective bipolar 
disorder (SAB: 977 cases, 8,690 controls), a mood disorder including psychotic 
symptoms. Controls are shared across these subtype analyses.  
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Subtype GWAS were not available from PGC MDD. Instead, a major 
depressive disorder cohort was derived from the online mental health questionnaire 
in the UK Biobank (UKB MDD: 29,475 cases, 63,482 controls; Resource 22 on 
1 
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3 
http://biobank.ctsu.ox.ac.uk) (18). The definition of major depressive disorder in this 
cohort is based on DSM-5, as described in full elsewhere 
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(18), and in Supplementary 
Table 1 (7). Individuals meeting criteria for major depressive disorder were classed 
as “recurrent” if they reported multiple depressed periods across their lifetime (rMDD, 
N = 17,451), and “single-episode” otherwise (sMDD, N = 12,024, Supplementary 
Table 1). Individuals reporting depressive symptoms but not meeting case criteria 
were excluded from UKB MDD but used as a "sub-threshold depression" subtype to 
examine the continuity of genetic associations with major depressive disorder below 
clinical thresholds (subMDD, N = 21,596). All subtypes were analysed with all 
controls. Details on the quality control and analysis of the UK Biobank phenotypes is 
provided in the Supplementary Methods.  
Meta-analysis of GWAS data 15 
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 We meta-analysed PGC MDD and UKB MDD to obtain a single major 
depressive disorder GWAS (combined MDD). We meta-analysed combined MDD 
with PGC BD, comparing mood disorder cases to controls (MOOD). Further meta-
analyses were performed between PGC MDD and each mood disorder subtype to 
assess the relative increase in variant discovery when adding different mood 
disorder definitions to PGC MDD (Supplementary Results).  
Summary statistics were limited to common variants (MAF > 0.05; 
Supplementary Methods) genotyped or imputed with high confidence (INFO score > 
0.6) in all studies. Controls were shared between PGC MDD and PGC BD, and 
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(because PGC MDD included summary data) the extent of this overlap was 
unknown. Meta-analyses were therefore performed in METACARPA, which controls 
for sample overlap of unknown extent between studies using the variance-
covariance matrix of the observed effect sizes at each variant, weighted by the 
sample sizes 
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(21, 22). METACARPA adjusted adequately for known overlap 
between cohorts (Supplementary Methods). For later analyses (particularly linkage 
disequilibrium score regression) we used as the sample size a "non-overlapping N" 
estimated for each meta-analysis (Supplementary Methods). The definition, 
annotation and visualisation of each meta-analysis is described in the 
Supplementary Materials.  
Sensitivity analysis using down-sampled PGC MDD 11 
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Cross-trait meta-analyses may be biased if the power of the composite 
analyses differs substantially (23, 24). The mean chi-square of combined MDD [1.7] 
exceeded that of PGC BD [1.39], suggesting this bias may affect our results 
(Supplementary Table 2). We therefore repeated our analyses, meta-analysing UKB 
MDD with summary statistics for PGC MDD that did not include participants from 
23andMe nor the UK Biobank (mean chi-square = 1.35). All analyses were 
performed on the full and the down-sampled analyses, with the exception of GSMR 
analyses. Full results of the down-sampled analyses are described in the 
Supplementary Materials.  
Estimation of SNP-based heritability and genetic correlations with published GWAS  21 
22 
23 
24 
Single nucleotide polymorphism (SNP)-based heritability was assessed using 
linkage disequilibrium score regression (LDSC) (25). SNP-based heritability 
estimates were transformed to the liability scale, assuming population prevalences of 
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15% for combined MDD, 1% for PGC BD, and 16% for MOOD, and lower and upper 
bounds of these prevalences for comparison (Supplementary Methods). LDSC 
separates genome-wide inflation into components due to polygenicity and 
confounding 
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(25). Inflation not due to polygenicity was quantified as (intercept-
1)/(mean observed chi-square-1) (26). Genetic correlations were calculated in LDSC 
between each analysis and 414 traits curated from published GWAS. Local 
estimates of SNP-based heritability and genetic covariance were obtained using 
HESS v0.5.3b (Supplementary Methods and Results) (27, 28).  
Genetic correlations between subtype analyses 9 
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To assess the structure of genetic correlations within the mood disorders, 
SNP-based heritabilities and genetic correlations were calculated in LDSC between 
bipolar disorder subtypes (BD1, BD2, SAB), and major depressive disorder subtypes 
(rMDD, sMDD, subMDD). Putative differences between genetic correlations were 
identified using a z-test (p < 0.05), and formally tested by applying a block-jackknife, 
with Bonferroni correction for significance (p < 8.3x10-4; Supplementary Methods). 
Differences between the genetic correlations of PGC MDD and each bipolar disorder 
subtype, and between PGC BD and each major depressive disorder subtype were 
also tested (Bonferroni correction for significance, p < 0.0083). Genetic correlations 
were hierarchically clustered using the gplots package in R v1.4.1 (29, 30). 
Hierarchical clustering was performed using just the subtypes, and including results 
from six external GWAS relevant to mood disorders (Supplementary Methods). To 
validate our conclusion of a genetic mood disorder spectrum, we performed principal 
component analysis of the genetic correlation matrix including the six external 
GWAS (Supplementary Methods and Results).
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 1 
Association of PGC BD polygenic risk scores with major depressive disorder 2 
subtypes 3 
4 
5 
6 
Polygenic risk score analyses were performed using PRSice2 to assess 
whether rMDD was genetically more similar to PGC BD than were sMDD or subMDD 
(Supplementary Methods) (36). 
Gene-wise, gene-set, and tissue and single-cell enrichment analyses 7 
8 
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For all analyses, the p-values of SNPs in gene regions were combined to yield 
gene-wide p-values, using MAGMA v1.06 (Supplementary Methods and Results) 
(37). Gene set analysis was performed in MAGMA (Supplementary Methods and 
Results). Further analyses were performed to assess the enrichment of associated 
genes with expression-specificity profiles from tissues (Genotype-Tissue Expression 
project, version 7) and broadly-defined ("level 1") and narrowly-defined ("level 2") 
mouse brain cell-types (38, 39). Analyses were performed in MAGMA following 
previously described methods with minor modifications, with Bonferroni-correction for 
significance (Supplementary Methods) (38). Similar analyses can be performed in 
LDSC-SEG – we report MAGMA results, which reflect specificity of expression 
across the range, whereas LDSC-SEG compares the top 10% of the range with the 
remainder (40). Results using LDSC are included in the Supplementary Tables.  
Mendelian randomisation (GSMR) 20 
21 
22 
23 
Bidirectional Mendelian randomisation analyses were performed using the 
GSMR option in GCTA to allow exploratory inference of the causal direction of 
known relationships between mood disorder traits and other traits (41, 42). 
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Specifically, the relationship between the mood disorder analyses (MOOD, combined 
MDD, PGC BD) and schizophrenia, intelligence, educational attainment, body mass 
index, and coronary artery disease were explored (Supplementary Methods) 
1 
2 
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6 
(32, 
43–46). These traits were previously examined in the PGC major depression GWAS 
– we additionally tested intelligence following the results of our genetic correlation 
analyses (15). 
Conditional and reversed-effect analyses 7 
8 
9 
10 
11 
12 
13 
14 
15 
Additional analyses were performed to identify shared and distinct mood 
disorder loci, using mtCOJO, an extension of GSMR (Supplementary Methods) (41, 
42). Analyses were performed on combined MDD conditional on PGC BD, and on 
PGC BD conditional on combined MDD (Supplementary Results). To identify loci 
with opposite directions of effect between combined MDD and PGC BD, the MOOD 
meta-analysis was repeated with reversed direction of effects for PGC BD 
(Supplementary Methods and Results). 
 
Results 16 
Evidence for confounding in meta-analyses  17 
18 
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Meta-analysis results were assessed for genome-wide inflation of test 
statistics using LDSC (25). Generally, the LDSC intercept was significantly >1 (1.00-
1.06), which has previously been interpreted as confounding (Supplementary Table 
2). However, such inflation can occur in large cohorts without confounding (47). 
Estimates of inflation not due to polygenicity were small in all meta-analyses (4-7%, 
Supplementary Table 2).
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Combined MOOD meta-analysis 2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
 We meta-analysed the PGC MDD, PGC BD and UKB MDD cohorts (MOOD, 
cases = 185,285, controls = 439,741, non-overlapping N = 609,424). 73 loci reached 
genome-wide significance, of which 55 were also seen in the meta-analysis of PGC 
MDD and UKB MDD (combined MDD, Table 1, Supplementary Table 3, 
Supplementary Figures 1-8). 39 of the 44 PGC MDD loci reached genome-wide 
significance in MOOD. In comparison, only four of the 19 PGC BD loci reached 
genome-wide significance in MOOD (Supplementary Table 3). MOOD loci 
overlapped considerably with previous studies of depression and depressive 
symptoms (51/73) (20, 23, 48–52), bipolar disorder (3/73) (53–56), neuroticism 
(32/73) (23, 57–59), and schizophrenia (15/73) (32, 60), although participants 
overlap between MOOD and many of these studies. Locus 52 (chromosome 12) 
passed genome-wide significance in a previous meta-analysis of broad depression 
and bipolar disorder, although the two other loci from this study did not replicate (51). 
Six of the 73 associations are entirely novel (p > 5x10-8 in previous studies of all 
phenotypes; Table 1, Supplementary Table 4). 
Down-sampled MOOD (cases = 95,481, controls = 287,932, non-overlapping 
N = 280,214) showed increased similarity to PGC BD compared to MOOD, but 
remained more similar to PGC MDD. Nineteen loci reached genome-wide 
significance in down-sampled MOOD, including nine (20%) from PGC MDD, 
compared with two (11%) reported in PGC BD (Supplementary Table 3). 17/19 loci 
were also observed in MOOD. Of the two loci not observed in MOOD, one passed 
genome-wide significance in PGC BD. 
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SNP-based heritability and genetic correlations  2 
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The estimate of SNP-based heritability for MOOD (8.8%) was closer to PGC 
MDD (8.8%) than to PGC BD (20%). Significant genetic correlations between MOOD 
and other traits included psychiatric and behavioural, reproductive, cardiometabolic, 
and sociodemographic traits (Figure 1, Supplementary Table 5). Genetic correlations 
with psychiatric and behavioural traits are consistently observed across psychiatric 
traits (17, 61). The genetic correlation between MOOD and educational attainment 
was -0.06 (p=0.004), intermediate between the results of combined MDD (rg = -0.11) 
and of PGC BD (rg = 0.19; Supplementary Table 6). Notably, the genetic correlation 
with intelligence was not significant in any of the three analyses (p>1.27x10-4). 
However, sensitivity analyses (see below), indicated that including 23andMe in PGC 
MDD obscured a negative genetic correlation with intelligence. 
The SNP-based heritability of down-sampled MOOD from LDSC was 11%, 
closer to PGC MDD than to PGC BD (Supplementary Table 2). Genetic correlations 
varied (Supplementary Tables 5 and 7) with some more similar to PGC BD 
(schizophrenia: down-sampled rg = 0.61, combined MDD rg = 0.35, PGC BD rg = 
0.7), and others more similar to combined MDD (ADHD: down-sampled rg = 0.48, 
combined MDD rg = 0.45, PGC BD rg = 0.14). The genetic correlation with 
intelligence was significant (rg = -0.13, p = 5x10
-7), because the excluded 23andMe 
depression cohort has a positive genetic correlation with intelligence (rg = 0.06, p = 
0.01). The greater genetic correlation of MOOD with combined MDD (rg = 0.98) 
compared to PGC BD (rg = 0.55) persisted when comparing down-sampled MOOD 
to combined MDD (rg = 0.85) and PGC BD (rg = 0.75; Supplementary Table 6).  
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Relationship between mood disorder subtypes 2 
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 Analyses were performed using GWAS data from subtypes of bipolar disorder 
(BD1, BD2, SAB) and major depressive disorder (rMDD, sMDD, subMDD). SNP-
based heritability for the subtypes ranged from subMDD and sMDD (8%), through 
BD2 and rMDD (10% and 12%, respectively) to BD1 and SAB (22% and 29% 
respectively, Figure 2, Supplementary Table 2).  
The major depressive disorder subtypes were strongly and significantly 
genetically correlated (rg = 0.9-0.94, prg = 0 < 8.3x10
-4). These correlations did not 
differ significantly from 1 (all prg = 1 > 0.3), nor from each other (all p∆rg = 0 > 0.5, Figure 
2, Supplementary Table 8). BD1 and SAB were strongly correlated (rg = 0.77, prg = 0 = 
6x10-13, prg = 1 = 0.03), as were BD1 and BD2 (rg = 0.86, prg = 0 = 3x10
-16, prg = 1 = 0.2). 
However, BD2 was not significantly correlated with SAB (rg = 0.22, prg = 0 = 0.02). 
In hierarchical clustering, BD2 clustered with the major depressive disorder 
subtypes rather than the bipolar disorder subtypes. The strength of correlation 
between BD2 and BD1 did not differ from that between BD2 and rMDD (rg = 0.68, prg 
= 0 = 3x10
-8, prg = 1 = 0.01), following multiple testing correction (∆rg = 0.18, p = 0.02). 
Overall, these results suggest a spectrum of genetic relationships between major 
depressive disorder and bipolar disorder, with BD2 bridging the two disorders (Figure 
3; Supplementary Figure 9). This spectrum remained when six external phenotypes 
were added, and was supported by results from principal component analysis 
(Supplementary Results, Supplementary Figure 10).  
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 Polygenic risk score analyses showed that individuals with high polygenic risk 
scores for PGC BD were more likely to report rMDD than sMDD, and more likely to 
report sMDD than subMDD (Supplementary Results). 
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Tissue and cell-type specificity analyses 4 
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The results of gene-wise and gene set analyses are described in the 
Supplementary Results. The tissue-specificity of associated genes differed minimally 
between the analyses (Supplementary Table 9). All brain regions were significantly 
enriched in all analyses, and the pituitary was also enriched in combined MDD and 
PGC BD (p < 9.43x10-4, Bonferroni correction for 53 regions, Supplementary Table 
9). Results from down-sampled MOOD and down-sampled MDD were generally 
consistent with the main analyses, except spinal cord was not enriched in either, nor 
was the cordate in the down-sampled MDD analysis.  
In contrast, cell-type enrichments differed between combined MDD and PGC 
BD (Figure 4, Supplementary Tables 10 and 11). Genes associated with PGC BD 
were enriched for expression in pyramidal cells from the CA1 region of the 
hippocampus and the somatosensory cortex, and in striatal interneurons. None of 
these enrichments were significant in combined MDD. Genes only associated with 
combined MDD were significantly enriched for expression in neuroblasts and 
dopaminergic neurons from adult mice. Further cell-types (dopaminergic 
neuroblasts; dopaminergic, GABAergic and midbrain nucleus neurons from 
embryonic mice; interneurons; and medium spiny neurons) were enriched for both 
combined MDD and PGC BD, but the rank and strength of enrichment differed, most 
notably for medium spiny neurons. The general pattern of differences persisted when 
comparing PGC BD with down-sampled MDD, although genes associated with 
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down-sampled MDD were not enriched for expression in adult dopaminergic 
neurons, embryonic midbrain nucleus neurons, interneurons, nor medium spiny 
neurons (Supplementary Figure 11). 
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Shared and distinct relationships with mood disorders and inferred causality 4 
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Bidirectional Mendelian randomisation was used to investigate previously-
described relationships between mood disorder phenotypes (combined MDD, PGC 
BD) and external traits: schizophrenia, educational attainment, intelligence, body 
mass index (BMI) and coronary artery disease (CAD; Figure 5, Supplementary Table 
12).  
Positive bidirectional relationships were observed between combined MDD, 
PGC BD, and schizophrenia. This is consistent with psychiatric disorders causing 
further psychiatric disorders, or being correlated with other causal risk factors, 
including (but not limited to) a shared genetic basis. 
There was a negative bidirectional relationship between educational years 
and combined MDD, but a positive bidirectional relationship with PGC BD (albeit with 
only nominal significance from PGC BD to educational years). In contrast, no 
significant relationship was observed between mood phenotypes and intelligence. 
This is consistent with differing causal roles of education (or its correlates) on the 
mood disorders, with a weaker reciprocal effect of the mood disorders altering the 
length of education.  
A positive association was seen from BMI to combined MDD, but not from 
combined MDD to BMI. In contrast, only a nominally significant negative relationship 
16 
 
was seen from PGC BD to BMI. A positive association was observed from combined 
MDD to CAD; no relationship was observed between CAD and PGC BD.  
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We identified 73 genetic loci by meta-analysing cohorts of major depression 
and bipolar disorder, including 15 loci novel to mood disorders. Our mood disorders 
meta-analysis results (MOOD) are more like our major depressive disorder analysis 
(combined MDD) than our bipolar disorder analysis (PGC BD). Partly, this results 
from the greater power of the major depressive disorder analysis compared to the 
bipolar disorder analysis. Nevertheless, genetic associations from our sensitivity 
analysis with equivalently powered cohorts (using down-sampled MDD instead of 
combined MDD) still showed a greater similarity to those from major depressive 
disorder rather than bipolar disorder. 
This may reflect a complex genetic architecture in bipolar disorder, wherein 
one set of variants may be associated more with manic symptoms and another set 
with depressive symptoms. Variants associated more with mania may have higher 
effect sizes, detectable at current bipolar disorder GWAS sample sizes, and may not 
be strongly associated with major depressive disorder. This could contribute to the 
higher heritability of bipolar disorder compared to major depressive disorder, and 
agrees with reports that most of the genetic variance for mania is not shared with 
depression (13, 14). Meta-analysis of bipolar disorder and major depressive disorder 
cohorts would support variants associated more with depression, but not those 
associated with mania. This is consistent with our findings, and with depressive 
symptoms being both the unifying feature of the mood disorders and the core feature 
of major depressive disorder. 
We examined the genetic relationship between mood disorder subtypes, 
including adding relevant external traits for context (Supplementary Results). Bipolar 
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disorder type 2 showed greater genetic similarity to major depressive disorder 
compared to type 1, mirroring similar findings from polygenic risk scores analyses 
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(16, 56). Individuals with high polygenic risk scores for PGC BD were more likely to 
report recurrent than single-episode major depressive disorder. However, the genetic 
correlation of PGC BD with recurrent major depressive disorder was not significantly 
greater than that with single-episode major depressive disorder. This might reflect 
the difference in power between these methods. Genetic correlations between mood 
disorder subtypes support a genetic mood spectrum, with the schizophrenia-like 
bipolar disorder type 1 and schizoaffective disorder at one pole, and the depressive 
disorders at the other, with bipolar disorder type 2 occupying an intermediate 
position. 
Conditional and reversed-effect analyses (Supplementary Results) suggest 
that few of the loci we identified are disorder-specific. Nonetheless we observed 
some genetic differences between the mood disorders. The expression specificity of 
associated genes in mouse brain cell-types differed between bipolar disorder and 
major depressive disorder. Cell-types more associated with bipolar disorder 
(pyramidal neurons and striatal interneurons) were also enriched in analyses of 
schizophrenia (38). Cell-types more associated in major depressive disorder 
(neuroblasts, adult dopaminergic neurons, embryonic GABAergic neurons) had 
weaker enrichments in schizophrenia, but were enriched in analyses of neuroticism 
(57). The higher rank of serotonergic neurons in major depressive disorder 
compared to bipolar disorder is striking given the use of drugs targeting the 
serotonergic system in treating depression (63). Nevertheless, cell-type enrichment 
analyses require cautious interpretation, especially given the use of non-human 
reference data (38, 64).  
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We explored potential causal relationships between the mood disorders and 
other traits using Mendelian randomisation. Interpreting these analyses is 
challenging, especially for complex traits, when the ascertainment of cases varies, 
and when few (< 20) variants are used as instruments (as in the PGC BD and down-
sampled analyses presented) 
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(41, 67, 68). Mood disorders demonstrate 
considerable heterogeneity, potentially confounding the results of Mendelian 
randomisation. That said, our results are consistent with a bidirectional influence of 
educational attainment on risk for mood disorders (and vice versa), with different 
directions of effect in the two mood disorders. We found no significant relationship 
between intelligence and either mood disorder. We also find results consistent with 
major depressive disorder increasing the risk for coronary artery disease in a 
relatively well powered analysis. This mirrors epidemiological findings, although the 
mechanism remains unclear (69). 
Despite the presence of depressive episodes, the mood disorders are 
diagnostically distinct, with differing epidemiology – for example, more women than 
men suffer from major depressive disorder, whereas diagnoses of bipolar disorder 
are roughly equal between the sexes (3). Differences in our genetic results between 
major depressive disorder and bipolar disorder may result from epidemiological 
heterogeneity, rather than distinct biological mechanisms (70). Deeper phenotyping 
of GWAS datasets is ongoing, and will enable the effect of such confounding factors 
to be estimated in future studies (71). 
We extend previous findings showing genetic continuity across the mood 
disorders (15–17, 56). Combined mood disorder analyses may increase variant 
discovery, as well as the discovery of shared and distinct neurobiological gene sets 
and cell-types. Our results indicate some genetic differences between major 
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depressive disorder and bipolar disorder, including opposite bidirectional 
relationships of each with educational attainment, a possible influence of major 
depressive disorder on coronary artery disease risk, and differing mouse brain cell-
types implicated by the enrichment patterns of associated genes in each disorder. 
Finally, our data are consistent with a genetic mood disorder spectrum with separate 
clusters for bipolar disorder type 1 and depressive disorders, linked by bipolar 
disorder type 2, and with depression as the common symptom. The identification of 
specific sets of genetic variants differentially associated with depression and with 
mania remains an aim for future research.  
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Figure Legends 
Figure 1: Selected genetic correlations of a) psychiatric traits and b) other traits with 
the main meta-analysis (MOOD), the separate mood disorder analyses (combined 
MDD and PGC BD), and the down-sampled analyses (down-sampled MOOD, down-
sampled MDD). Full genetic correlation results are provided in Supplementary Table 
5. 
Figure 2: SNP-based heritability estimates for the subtypes of bipolar disorder and 
subtypes of major depressive disorder. Points = SNP-based heritability estimates. 
Lines = 95% confidence intervals. Full SNP-based heritability results are provided in 
Supplementary Table 2. 
Figure 3: Genetic correlations across the mood disorder spectrum. Labelled arrows 
show genetic correlations significantly different from 0. Solid arrows represent 
genetic correlations not significantly different from 1 (p < 0.00333, Bonferroni 
correction for 15 tests). Full results are provided in Supplementary Table 8. 
Figure 4: Cell-type expression specificity of genes associated with bipolar disorder 
(PGC BIP, left) and major depressive disorder (combined MDD, right). Black vertical 
lines = significant enrichment (p < 2x10-3, Bonferroni correction for 24 cell-types). 
See Supplementary Table 10 for full results. 
Figure 5: GSMR results from analyses with the main meta-analysis (MOOD), and the 
major depression and bipolar disorder analyses (combined MDD, PGC BD). External 
traits are coronary artery disease (CAD), educational attainment (EDU), body mass 
index (BMI), and schizophrenia (SCZ). Betas are on the scale of the outcome GWAS 
46 
 
(logit for binary traits, phenotype scale for continuous). * p < 0.004 (Bonferroni 
correction for two-way comparisons with six external traits). For figure data, including 
the number of non-pleiotropic SNPs included in each instrument, see Supplementary 
Table 12. 
 
Data availability 
GWAS results from analyses including 23andMe are restricted by a data transfer 
agreement with 23andMe. For these analyses, LD-independent sets of 10,000 SNPs 
will be made available via the Psychiatric Genetics Consortium 
(https://www.med.unc.edu/pgc/results-and-downloads). Summary statistics not 
including 23andMe will be made available via the Psychiatric Genetics Consortium 
(https://www.med.unc.edu/pgc/results-and-downloads).
47 
 
 
Tables 
Locus Chr BP Index SNP A1 A2 OR SE p Previous report 
1 1 37192741 rs1002656 T C 0.97 0.005 2.71x10-11 DO, N 
2 1 72837239 rs7531118 T C 0.96 0.004 1.05x10-16 D, DO, S, O 
4 1 80795989 rs6667297 A G 0.97 0.005 5.86x10-11 D, DO 
5 1 90796053 rs4261101 A G 0.97 0.005 1.78x10-8 D 
6 1 175913828 rs10913112 T C 0.97 0.005 1.46x10-10 DO, O 
7 1 177370033 rs16851203 T C 0.96 0.007 2.38x10-9 DO, S, O 
9 2 22582968 rs61533748 T C 0.97 0.004 3.84x10-11 DO, N 
10 2 57987593 rs11682175 T C 0.97 0.004 2.18x10-11 D, DO, BS, N, S, O
11 2 157111313 rs1226412 T C 1.03 0.005 1.27x10-8 D, DO, N, O 
12 2 198807015 rs1518367 A T 0.97 0.005 1.18x10-8 BS, S, O 
13 3 108148557 rs1531188 T C 0.96 0.006 1.61x10-9 O 
14 3 158107180 rs7430565 A G 0.97 0.004 2.30x10-11 D, DO, N, O 
16 4 42047778 rs34215985 C G 0.97 0.006 1.72x10-10 D, DO, N 
17 5 77709430 rs4529173 T C 0.97 0.005 4.29x10-9 O 
18 5 88002653 rs447801 T C 1.03 0.004 2.29x10-10 D, DO, N, O 
19 5 92995013 rs71639293 A G 1.03 0.005 5.85x10-9 DO, N 
20 5 103904226 rs12658032 A G 1.04 0.005 2.19x10-16 D, DO, N, O 
21 5 106603482 rs55993664 A C 0.97 0.006 1.87x10-8 NOVEL LOCUS 
22 5 124251883 rs116755193 T C 0.97 0.005 1.47x10-10 D, O 
23 5 164523472 rs11135349 A C 0.97 0.004 2.96x10-11 D, DO, N 
24 5 166992078 rs4869056 A G 0.97 0.005 5.21x10-9 D 
25 6 28673998 rs145410455 A G 0.94 0.007 7.17x10-18 
D, DO, BO, BS, 
DS, N, S, O 
26 6 101339400 rs7771570 T C 0.97 0.004 9.68x10-10 DO, N, O 
27 6 105365891 rs1933802 C G 0.98 0.004 1.05x10-8 DO, S, O 
28 7 12267221 rs4721057 A G 0.97 0.004 7.31x10-11 D, DO, N, O 
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29 7 24826589 rs79879286 C G 1.04 0.006 1.97x10-11 B, BS, DO, S 
30 7 82514089 rs34866621 T C 1.03 0.005 2.21x10-8 DO, O 
31 7 109099919 rs58104186 A G 1.03 0.004 7.12x10-9 D, DO 
34 9 11379630 rs10959753 T C 0.96 0.005 1.45x10-13 D, DO, N, O 
35 9 37207269 rs4526442 T C 0.96 0.006 7.97x10-11 DO, O 
36 9 81413414 rs11137850 A G 1.03 0.005 1.25x10-8 NOVEL LOCUS 
38 9 119733380 rs10759881 A C 1.03 0.005 8.56x10-9 D, DO 
40 9 122664468 rs10818400 T G 0.98 0.004 1.29x10-8 N 
41 9 126682068 rs7029033 T C 1.04 0.008 2.61x10-8 D, DO, O 
42 10 104684544 rs78821730 A G 0.96 0.007 2.95x10-8 N, BS, S, O 
43 10 106563924 rs61867293 T C 0.96 0.005 5.64x10-12 D, DO, N, O 
44 11 16293680 rs977509 T C 0.97 0.005 1.19x10-8 DO, N, O 
45 11 31850105 rs1806153 T G 1.03 0.005 2.81x10-9 D, DO, N, O 
46 11 32765866 rs143864773 T C 1.04 0.008 1.70x10-8 NOVEL LOCUS 
47 11 61557803 rs102275 T C 0.97 0.005 5.04x10-11 B, DO, BO, O 
48 11 63632673 rs10792422 T G 0.98 0.004 2.18x10-8 O 
49 11 88743208 rs4753209 A T 0.97 0.004 4.15x10-9 DO, N, O 
50 11 99268617 rs1504721 A C 0.98 0.004 2.24x10-8 O 
51 11 113392994 rs2514218 T C 0.97 0.005 3.22x10-10 DO, BS, N, S, O 
52 12 2344644 rs769087 A G 1.03 0.005 3.27x10-8 
B, BD, BO, DS, 
BS, S, O 
53 12 23947737 rs4074723 A C 0.97 0.004 3.18x10-9 D, DO, N, O 
54 12 121186246 rs58235352 A G 0.95 0.009 1.64x10-10 DO, O 
55 12 121907336 rs7962128 A G 1.02 0.004 3.63x10-8 NOVEL LOCUS 
56 13 44327799 rs4143229 A C 0.95 0.008 2.73x10-10 D 
57 13 53625781 rs12552 A G 1.04 0.004 1.25x10-23 D, DO, O 
58 14 42074726 rs61990288 A G 0.97 0.004 2.29x10-10 D, DO, O 
60 14 64686207 rs915057 A G 0.98 0.004 1.92x10-8 D, DO, O 
61 14 75130235 rs1045430 T G 0.97 0.004 9.83x10-11 D, DO, N, O 
62 14 104017953 rs10149470 A G 0.97 0.004 1.15x10-10 
D, DS, DO, BS, S, 
O 
49 
 
50 
 
63 15 36355868 rs1828385 A C 0.97 0.004 1.15x10-8 NOVEL LOCUS 
64 15 37643831 rs8037355 T C 0.97 0.004 4.09x10-15 D, DO, O 
65 16 6310645 rs8063603 A G 0.97 0.005 5.36x10-11 D, DO 
66 16 7667332 rs11077206 C G 1.03 0.004 5.49x10-10 D, DO, N, O 
67 16 13038723 rs12935276 T G 0.97 0.005 4.75x10-10 D, DO, N, O 
68 16 13750257 rs7403810 T G 1.03 0.005 7.52x10-11 DO, BS, S, O 
69 16 72214276 rs11643192 A C 1.03 0.004 1.46x10-11 D, O 
70 17 27363750 rs75581564 A G 1.04 0.006 2.47x10-10 D, DO, O 
71 18 31349072 rs4534926 C G 1.03 0.004 9.14x10-9 DO, N 
72 18 36883737 rs62099069 A T 0.97 0.004 9.52x10-10 D, O 
73 18 42260348 rs117763335 T C 0.97 0.005 1.33x10-8 O 
74 18 50614732 rs11663393 A G 1.03 0.004 1.56x10-10 D, DO, N, O 
75 18 52517906 rs1833288 A G 1.03 0.005 4.54x10-8 
D, DS, DO, N, S, 
O 
76 18 53101598 rs12958048 A G 1.04 0.005 4.86x10-14 D, DO, BS, N, S, O
77 19 30939989 rs33431 T C 1.02 0.004 4.04x10-8 DO, O 
78 20 45841052 rs910187 A G 0.97 0.005 3.09x10-9 DO, O 
79 22 41621714 rs2179744 A G 1.03 0.005 3.83x10-12 
D, B, DO, BS, N, 
S, O 
80 22 42815358 rs7288411 A G 1.03 0.005 3.86x10-8 NOVEL LOCUS 
81 22 50679436 rs113872034 A G 0.96 0.006 1.10x10-9 O 
 
Table 1: Loci genome-wide significant (p < 5x10-8) in the MOOD meta-analysis.  
Locus – shared locus number for annotation (Supplementary Table 3), Chr – chromosome, 
BP – base position, A1 – effect allele, A2 – non-effect allele, Previous report – locus 
previously implicated in PGC MDD (D), PGC BD (B), previous combined studies of bipolar 
disorder and major depressive disorder (BD), other studies of major depressive disorder or 
depressive symptoms (DO), other studies of bipolar disorder (BO), previous combined 
studies of bipolar disorder and schizophrenia (BS), previous combined studies of major 
depressive disorder and schizophrenia (DS), neuroticism (N), schizophrenia (S), or other 
studies (O – see Supplementary Table 4). 
A)
B)


Major depressive disorderBipolar disorder

Resource Type
Add additional rows as needed for each 
Specific Reagent or Resource
Include species and sex when applicable.
resource type
Deposited Data; Public Database Human DNA samples and data
Deposited Data; Public Database Human DNA samples and data
Software; Algorithm miscellaeous scripts for the handling of GWAS data
Software; Algorithm RICOPILI; the primary software pipeline used by the 
Software; Algorithm METACARPA; the primary metaanalyis sofware used
Software; Algorithm LD score software

Source or Reference
Include name of manufacturer, company,  
repository, individual, or research lab. 
Identifiers
Include catalog numbers, stock numbers, 
database IDs or accession numbers, and/or 
Include PMID or DOI for references; use RRIDs. RRIDs are highly encouraged; search 
“this paper” if new. for RRIDs at https://scicrunch.org/resources. 
https://www.ukbiobank.ac.uk/register‐apply/
https://www.med.unc.edu/pgc/shared-
https://github.com/JoniColeman
https://github.com/Ripkelab/ricopili
https://github.com/hmgu‐itg/metacarpa
https://github.com/bulik/ldsc
KEY RESOURCES TABLE

Additional Information
Include any additional information or 
notes if necessary.
S TABLE

Key Resource Table
The journals of the Society of Biological Psychiatry support efforts in the biomedical 
research community to improve transparency and reproducibility in published research. 
Thus, Biological Psychiatry  and Biological Psychiatry: Cognitive Neuroscience and 
Neuroimaging are pleased to participate in the initiative to include a Key Resources Table 
in published articles.
Authors are asked to submit this table at first revision, which may be uploaded using the 
"Key Resources Table" item type. This table will then be published as supplemental 
information.
The Key Resources Table is designed to promote reproducibility and thus, should include 
the resources and relevant details necessary to reproduce the study's results. It does not 
need to be exhaustive. Extensive lists (e.g., oligonucleotides, etc.) may be supplied in a 
supplementary table and the table referenced here. We strongly encourage the use of 
RRID identifiers that provide persistent, unique identifiers to key study resources. Search 
Resource categories
Note: For all categories, indicate sex and species when applicable
●      Antibody - include host organism common name and clonality (e.g., “mouse mono
●      Biological sample - any other biological entity, ranging from isolated tissue to def
●      Cell line -  if a primary cell line, describe in Additional Information
●      Chemical compound, drug -  commercially available reagents
●      Commercial assay/kit - detection assays; labeling and sample preparation kits
●      Deposited data or public database - include both raw data from this paper 
deposited into a repository and public 
repository databases (postmortem tissue; genetic consortia data; etc )
●      Genetic reagent -  applies to mutations and variants in whole organism, including
●      Peptide, recombinant protein - commercially available reagents
●      Recombinant DNA reagent - traditional cultured clones, plasmids, cDNAs, etc., in
●      Sequence-based reagent - oligonucleotides, primers, etc.; indicate sequence
●      Software, algorithm - include version number and URL for download
●      Organism/Strain - applies to whole organism
●      Transfected construct - in cell line; indicate species of cell line or construct comp
●      Other - miscellaneous other categories, including histological stains
oclonal”)
fined population
g transgenically introduced constructs
ncluding recombinant DNA libraries
ponent
Resource Type
Add additional rows as needed for each 
Specific Reagent or Resource
Include species and sex when applicable.
resource type
Antibody rabbit anti-E2F2
Antibody total actin
Antibody E2F3
Bacterial or Viral Strain AAV-hSyn-DIO-hM3D(Gq)-mCherry
Bacterial or Viral Strain HSV-wtSmurf1
Biological Sample postmortem brain tissue
Cell Line control 03231 iPSC line 
Chemical Compound, Drug Terazosin
Commercial Assay Or Kit
Commercial Assay Or Kit
Bio-Rad DC Protein Assay
TruSeq Stranded mRNA Sample Prep Kit v2, , ,
Deposited Data; Public Database GSE13564, GSE80655, and GSE25219 
Organism/Strain Mouse: C57BL/6J, male
Sequence-Based Reagent Primers for RT-qPCR, see Table S1
Software; Algorithm HTSeq Python package
Software; Algorithm MATLAB v9.1


Source or Reference
Include name of manufacturer, company,  
repository, individual, or research lab. Include 
Identifiers
Include catalog numbers, stock numbers, 
database IDs or accession numbers, and/or 
PMID or DOI for references; use “this paper” 
if new.
RRIDs. RRIDs are highly encouraged; search 
for RRIDs at https://scicrunch.org/resources. 
Abcam Abcam Cat# ab50917, RRID:AB_869541
MP Biomedicals Cat#8691002, RRID:AB_2335304
Santa Cruz C-18, Cat#SC-878, RRID:AB_2096807
University of North Carolina Vector Core N/A
PMID: 10458166 Addgene plasmid # 11752
Harvard Brain Tissue Resource Center RRID:SCR_003316
National Institute of Neurological 
Disorders and Stroke repository NINDS # ND03231; RRID:SCR_004520
Sigma-Aldrich N/A
Bio-Rad Laboratories, Inc.
Illumina, Inc.
# 5000111
Cat. No. RS-122-2101_ ;
NCBI GEO DataSets https://www.ncbi.nlm.nih.gov/gds
The Jackson Laboratory RRID:IMSR_JAX:000664
This paper N/A
https://doi.org/10.1093/bioinformatics/btp120; 
https://doi.org/10.1093/bioinformatics/btu638 RRID:SCR_005514
Mathworks RRID:SCR_001622
EXAMPLE  KEY RESOURCES TABLE


Additional Information
Include any additional information or 
notes if necessary.
OURCES TABLE


Coleman et al.  Supplement 
 
1 
The Genetics of the Mood Disorder Spectrum: Genome-wide 
Association Analyses of Over 185,000 Cases and 439,000 Controls 
 
Supplement 1 
 
Contents 
 
Consortium Affiliations ................................................................................................ 4 
Supplementary Note ................................................................................................. 14 
Relationship between these analyses and recent depression analyses from the UK 
Biobank ............................................................................................................................. 14 
Supplementary Methods .......................................................................................... 14 
Participants ........................................................................................................................ 14 
Use of MAF > 0.05 as a cutoff ........................................................................................... 16 
Population prevalences ..................................................................................................... 17 
Definition of non-overlapping N ......................................................................................... 17 
Comparison of METACARPA with meta-analysis of independent cohorts........................ 18 
Definition of GWAS loci ..................................................................................................... 19 
Relationship between meta-analyses (hierarchical clustering) ......................................... 20 
Hierarchical clustering of genetic correlations between subtypes, and extension to 
examine relationships with related traits ........................................................................... 20 
Conditional and reversed-effect analyses ......................................................................... 21 
GSMR ................................................................................................................................ 23 
Comparing two genetic correlations using jackknife and LDSC ........................................ 23 
Estimating local SNP-based heritability and genetic covariance in HESS ........................ 24 
Gene-wise and gene-set enrichment analyses ................................................................. 25 
Tissue and single-cell enrichment analyses ...................................................................... 26 
Association with predicted brain tissue gene expression .................................................. 26 
Polygenic risk score prediction of UKB subtypes using PGC BD summary statistics ....... 27 
Supplementary Results ............................................................................................ 28 
Conditional analyses ......................................................................................................... 28 
Gene-wise and gene set analyses .................................................................................... 30 
Local SNP-based heritability and genetic covariance ....................................................... 31 
Genetic correlations of mood disorder subtypes ............................................................... 32 
Genetic correlations of PGC MDD and PGC BD with mood disorder subtypes ................ 34 
Coleman et al.  Supplement 
 
2 
Results from PGC MDD + subtype meta-analyses ........................................................... 34 
Bipolar disorder subtypes .............................................................................................. 34 
Major depressive disorder subtypes .............................................................................. 35 
Gains in discovery through adding individuals with different mood disorder diagnoses.... 36 
Associations of polygenic risk scores for PGC BD with UKB MDD subtypes.................... 37 
Relationship of meta-analysis results (hierarchical clustering) .......................................... 37 
Sensitivity analysis - Equivalently-powered cohorts .......................................................... 38 
Supplementary References ...................................................................................... 41 
Supplementary Figures ............................................................................................ 49 
Supplementary Figure 1 .................................................................................................... 49 
Supplementary Figure 2 .................................................................................................... 49 
Supplementary Figure 3 .................................................................................................... 50 
Supplementary Figure 4 .................................................................................................... 50 
Supplementary Figure 5 .................................................................................................... 51 
Supplementary Figure 6 .................................................................................................... 51 
Supplementary Figure 7 .................................................................................................... 52 
Supplementary Figure 8 .................................................................................................... 52 
Supplementary Figure 9 .................................................................................................... 53 
Supplementary Figure 10 .................................................................................................. 54 
Supplementary Figure 11 .................................................................................................. 55 
Supplementary Figure 12 .................................................................................................. 56 
Supplementary Figure 13 .................................................................................................. 58 
Supplementary Figure 14 .................................................................................................. 59 
Supplementary Figure 15 .................................................................................................. 60 
Supplementary Figure 16 .................................................................................................. 61 
Supplementary Figure 17 .................................................................................................. 62 
Supplementary Figure 18 .................................................................................................. 63 
Supplementary Figure 19 .................................................................................................. 64 
Supplementary Figure 20 .................................................................................................. 65 
Supplementary Figure 21 .................................................................................................. 66 
Supplementary Figure 22 .................................................................................................. 67 
Supplementary Figure 23 .................................................................................................. 68 
Supplementary Figure 24 .................................................................................................. 69 
Supplementary Figure 25 .................................................................................................. 70 
Supplementary Figure 26 .................................................................................................. 71 
Coleman et al.  Supplement 
 
3 
Supplementary Figure 27 .................................................................................................. 72 
Supplementary Figure 28 .................................................................................................. 73 
Supplementary Figure 29 .................................................................................................. 74 
Supplementary Figure 30 .................................................................................................. 75 
Supplementary Figure 31 .................................................................................................. 76 
Supplementary Figure 32 .................................................................................................. 77 
Supplementary Figure 33 .................................................................................................. 78 
Supplementary Figure 34 .................................................................................................. 79 
Supplementary Figure 35 .................................................................................................. 80 
Supplementary Figure 36 .................................................................................................. 81 
Supplementary Figure 37 .................................................................................................. 82 
Supplementary Figure 38 .................................................................................................. 83 
Supplementary Figure 39 .................................................................................................. 84 
Supplementary Figure 40 .................................................................................................. 85 
Supplementary Figure 41 .................................................................................................. 86 
Supplementary Figure 42 .................................................................................................. 87 
Supplementary Figure 43 .................................................................................................. 88 
Supplementary Figure 44 .................................................................................................. 89 
 
  
Coleman et al.  Supplement 
 
4 
Affiliations of Individual Authors from the Bipolar Disorder and Major 
Depressive Disorder Working Groups of the Psychiatric Genomics Consortium  
1       Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, 
Psychology and Neuroscience, King's College London, London, United 
Kingdom 
2       NIHR Maudsley Biomedical Research Centre, King's College London, 
London, United Kingdom 
3       Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 
Stockholm, Sweden 
4       Institute for Molecular Bioscience, The University of Queensland, Brisbane, 
QLD, Australia 
5       Human Genomics Research Group, Department of Biomedicine, University of 
Basel, Basel, Switzerland 
6       Department of Psychiatry (UPK), University of Basel, Basel, Switzerland 
7       Institute of Human Genetics, University of Bonn, School of Medicine & 
University Hospital Bonn, Bonn, Germany 
8       Department of Genomics, Life&Brain Center, University of Bonn, Bonn, 
Germany 
9       Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, 
Switzerland 
10     Medical Research Council Centre for Neuropsychiatric Genetics and 
Genomics, Division of Psychological Medicine and Clinical Neurosciences, 
Cardiff University, Cardiff, United Kingdom 
11     Department of Complex Trait Genetics, Center for Neurogenomics and 
Cognitive Research, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, 
Amsterdam, Netherlands 
12     iSEQ, Center for Integrative Sequencing, Aarhus University, Aarhus, Denmark 
13     Department of Biomedicine - Human Genetics, Aarhus University, Aarhus, 
Denmark 
14     Department of Clinical Neuroscience, Centre for Psychiatry Research, 
Karolinska Institutet, Stockholm, Sweden 
15     Department of Psychiatry, Psychosomatics and Psychotherapy, Center of 
Mental Health, University Hospital Würzburg, Würzburg, Germany 
16     iPSYCH, The Lundbeck Foundation Initiative for Psychiatric Research, 
Copenhagen, Denmark 
17     Division of Psychiatry, University College London, London, United Kingdom 
18     Queensland Brain Institute, The University of Queensland, Brisbane, QLD, 
Australia 
19     Medical and Population Genetics, Broad Institute, Cambridge, MA, USA 
20     Division of Endocrinology and Center for Basic and Translational Obesity 
Research, Boston Children’s Hospital, Boston, MA, USA 
21     Stanley Center for Psychiatric Research, Broad Institute, Cambridge, MA, 
USA 
22     Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin, 
Berlin, Germany 
23     Analytic and Translational Genetics Unit, Massachusetts General Hospital, 
Boston, MA, USA 
24     Department of Genetics and Genomic Sciences, Icahn School of Medicine at 
Mount Sinai, New York, NY, USA 
Coleman et al.  Supplement 
 
5 
25     Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New 
York, NY, USA 
26     deCODE Genetics / Amgen, Reykjavik, Iceland 
27     Institute of Biological Psychiatry, Mental Health Centre Sct. Hans, 
Copenhagen, Denmark 
28     Institute of Clinical Medicine, University of Oslo, Oslo, Norway 
29     Dept of Biological Psychology & EMGO+ Institute for Health and Care 
Research, Vrije Universiteit Amsterdam, Amsterdam, Netherlands 
30     Division of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom 
31     Department of Clinical Sciences, Psychiatry, Umeå University Medical 
Faculty, Umeå, Sweden 
32     National Centre for Register-Based Research, Aarhus University, Aarhus, 
Denmark 
33     Centre for Integrated Register-based Research, Aarhus University, Aarhus, 
Denmark 
34     Molecular & Behavioral Neuroscience Institute, University of Michigan, Ann 
Arbor, MI, USA 
35     Neuroscience, Istituto Di Ricerche Farmacologiche Mario Negri, Milano, Italy 
36     Department of Psychiatry and Behavioral Neuroscience, University of 
Chicago, Chicago, IL, USA 
37     Department of Translational Research in Psychiatry, Max Planck Institute of 
Psychiatry, Munich, Germany 
38     Department of Neurology, Klinikum rechts der Isar, Technical University of 
Munich, Munich, Germany 
39     Psychiatry, Berkshire Healthcare NHS Foundation Trust, Bracknell, United 
Kingdom 
40     Department of Psychiatry and Psychotherapy, University Medicine Greifswald, 
Greifswald, Mecklenburg-Vorpommern, Germany 
41     Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, 
USA 
42     Psychiatry, Rush University Medical Center, Chicago, IL, USA 
43     Center for Neonatal Screening, Department for Congenital Disorders, Statens 
Serum Institut, Copenhagen, Denmark 
44     Department of Psychiatry, Weill Cornell Medical College, New York, NY, USA 
45     Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav 
Carus, Technische Universität Dresden, Dresden, Germany 
46     Department of Psychiatry, Vrije Universiteit Medical Center and GGZ inGeest, 
Amsterdam, Netherlands 
47     Virginia Institute for Psychiatric and Behavior Genetics, Richmond, VA, USA 
48     Department of Psychiatry and Behavioral Sciences, Emory University School 
of Medicine, Atlanta, GA, USA 
49     Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway 
50     Psychiatry, UMC Utrecht Hersencentrum Rudolf Magnus, Utrecht, 
Netherlands 
51     Human Genetics, University of California Los Angeles, Los Angeles, CA, USA 
52     Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, 
LMU Munich, Munich, Germany 
53     Department of Psychiatry and Human Behavior, University of California, 
Irvine, Irvine, CA, USA 
Coleman et al.  Supplement 
 
6 
54     Molecular & Behavioral Neuroscience Institute and Department of 
Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, 
MI, USA 
55     iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric 
Research, Denmark 
56     Psychiatry, University of California San Francisco, San Francisco, CA, USA 
57     Human Genetics, Wellcome Trust Sanger Institute, Cambridge, United 
Kingdom 
58     Statistical genomics and systems genetics, European Bioinformatics Institute 
(EMBL-EBI), Cambridge, United Kingdom 
59     Instituto de Salud Carlos III, Biomedical Network Research Centre on Mental 
Health (CIBERSAM), Madrid, Spain 
60     Department of Psychiatry, Hospital Universitari Vall d´Hebron, Barcelona, 
Spain 
61     Department of Psychiatry and Forensic Medicine, Universitat Autònoma de 
Barcelona, Barcelona, Spain 
62     Psychiatric Genetics Unit, Group of Psychiatry Mental Health and Addictions, 
Vall d´Hebron Research Institut (VHIR), Universitat Autònoma de Barcelona, 
Barcelona, Spain 
63     Department of Psychiatry, University Hospital of Lausanne, Prilly, Vaud, 
Switzerland 
64     Department of Psychiatry, Mood Disorders Program, McGill University Health 
Center, Montreal, QC, Canada 
65     Institute for Medical Sciences, University of Aberdeen, Aberdeen, United 
Kingdom 
66     Genetics and Computational Biology, QIMR Berghofer Medical Research 
Institute, Brisbane, QLD, Australia 
67     University of Iowa Hospitals and Clinics, Iowa City, IA, USA 
68     Centre for Advanced Imaging, The University of Queensland, Brisbane, QLD, 
Australia 
69     Translational Genomics, USC, Phoenix, AZ, USA 
70     Center for Genomic and Computational Biology, Duke University, Durham, 
NC, USA 
71     Department of Pediatrics, Division of Medical Genetics, Duke University, 
Durham, NC, USA 
72     Department of Psychiatry, Laboratory of Psychiatric Genetics, Poznan 
University of Medical Sciences, Poznan, Poland 
73     Department of Neurosciences, University of California San Diego, La Jolla, 
CA, USA 
74     Department of Radiology, University of California San Diego, La Jolla, CA, 
USA 
75     Department of Psychiatry, University of California San Diego, La Jolla, CA, 
USA 
76     Department of Cognitive Science, University of California San Diego, La Jolla, 
CA, USA 
77     Centre for Cognitive Ageing and Cognitive Epidemiology, University of 
Edinburgh, Edinburgh, United Kingdom 
78     Applied Molecular Genomics Unit, VIB Department of Molecular Genetics, 
University of Antwerp, Antwerp, Belgium 
Coleman et al.  Supplement 
 
7 
79     Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, 
Baltimore, MD, USA 
80     Epidemiology, Erasmus MC, Rotterdam, Zuid-Holland, Netherlands 
81     Psychiatry, Dokuz Eylul University School Of Medicine, Izmir, Turkey 
82     Department of Medical Genetics, Oslo University Hospital Ullevål, Oslo, 
Norway 
83     NORMENT, KG Jebsen Centre for Psychosis Research, Department of 
Clinical Science, University of Bergen, Bergen, Norway 
84     Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA 
85     Psychiatric and Neurodevelopmental Genetics Unit (PNGU), Massachusetts 
General Hospital, Boston, MA, USA 
86     Department of Neurology, Oslo University Hospital, Oslo, Norway 
87     NORMENT, KG Jebsen Centre for Psychosis Research, Oslo University 
Hospital, Oslo, Norway 
88     Department of Epidemiology, Harvard T.H. Chan School of Public Health, 
Boston, MA, USA 
89     Department of Mathematics, Massachusetts Institute of Technology, 
Cambridge, MA, USA 
90     Center for Statistical Genetics and Department of Biostatistics, University of 
Michigan, Ann Arbor, MI, USA 
91     Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental 
Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, 
Germany 
92     Department of Medical & Molecular Genetics, Indiana University, Indianapolis, 
IN, USA 
93     Center for Neurobehavioral Genetics, University of California Los Angeles, 
Los Angeles, CA, USA 
94     Department of Molecular Medicine and Surgery, Karolinska Institutet and 
Center for Molecular Medicine, Karolinska University Hospital, Stockholm, 
Sweden 
95     Department of Clinical Neuroscience, Karolinska Institutet and Center for 
Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden 
96     Child and Adolescent Psychiatry Research Center, Stockholm, Sweden 
97     Department of Psychiatry and Psychotherapy, University Medical Center 
Göttingen, Göttingen, Germany 
98     Department of Psychiatry, Dalhousie University, Halifax, NS, Canada 
99     Psychiatry & Behavioral Sciences, Johns Hopkins University, Baltimore, MD, 
USA 
100  Department of Psychological Medicine, University of Worcester, Worcester, 
United Kingdom 
101  School of Biomedical and Healthcare Sciences, Plymouth University 
Peninsula Schools of Medicine and Dentistry, Plymouth, United Kingdom 
102  School of Psychiatry, University of New South Wales, Sydney, NSW, Australia 
103  Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark 
104  Biostatistics, University of Minnesota System, Minneapolis, MN, USA 
105  Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, 
United Kingdom 
106  Danish Headache Centre, Department of Neurology, Rigshospitalet, Glostrup, 
Denmark 
Coleman et al.  Supplement 
 
8 
107  Institute of Biological Psychiatry, MHC Sct. Hans, Mental Health Services 
Copenhagen, Roskilde, Denmark 
108  Department of Psychology, Eberhard Karls Universität Tübingen, Tubingen, 
Germany 
109  Department of Psychiatry, Leiden University Medical Center, Leiden, 
Netherlands 
110  Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia 
111  Department of Psychiatry and Behavioral Sciences, Howard University 
Hospital, Washington, DC, USA 
112  Center for Multimodal Imaging and Genetics, University of California San 
Diego, La Jolla, CA, USA 
113  Interfaculty Institute for Genetics and Functional Genomics, Department of 
Functional Genomics, University Medicine and Ernst Moritz Arndt University 
Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany 
114  Roche Pharmaceutical Research and Early Development, Pharmaceutical 
Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, 
Switzerland 
115  Max Planck Institute of Psychiatry, Munich, Germany 
116  Psychiatrie Translationnelle, Inserm U955, Créteil, France 
117  Faculté de Médecine, Université Paris Est, Créteil, France 
118  Division of Research, Kaiser Permanente Northern California, Oakland, CA, 
USA 
119  Campbell Family Mental Health Research Institute, Centre for Addiction and 
Mental Health, Toronto, ON, Canada 
120  Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, ON, 
Canada 
121  Department of Psychiatry, University of Toronto, Toronto, ON, Canada 
122  Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada 
123  Bioinformatics, University of British Columbia, Vancouver, BC, Canada 
124  Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, 
University Hospital Frankfurt, Frankfurt am Main, Germany 
125  Cell Biology, SUNY Downstate Medical Center College of Medicine, Brooklyn, 
NY, USA 
126  Institute for Genomic Health, SUNY Downstate Medical Center College of 
Medicine, Brooklyn, NY, USA 
127  Center for Research in Environmental Epidemiology (CREAL), Barcelona, 
Spain 
128  Department of Biomedical Informatics, Harvard Medical School, Boston, MA, 
USA 
129  Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA 
130  Informatics Program, Boston Children's Hospital, Boston, MA, USA 
131  Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, 
United Kingdom 
132  Department of Endocrinology at Herlev University Hospital, University of 
Copenhagen, Copenhagen, Denmark 
133  Psychiatry, Altrecht, Utrecht, Netherlands 
134  Institute of Social and Preventive Medicine (IUMSP), University Hospital of 
Lausanne, Lausanne, VD, Switzerland 
135  Swiss Institute of Bioinformatics, Lausanne, VD, Switzerland 
136  Psychiatry, North East London NHS Foundation Trust, Ilford, United Kingdom 
Coleman et al.  Supplement 
 
9 
137  Clinic for Psychiatry and Psychotherapy, University Hospital Cologne, 
Cologne, Germany 
138  Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General 
Hospital, Boston, MA, USA 
139  HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA 
140  Department of Human Genetics, University of Michigan, Ann Arbor, MI, USA 
141  Psychiatry, University of Illinois at Chicago College of Medicine, Chicago, IL, 
USA 
142  Mental Health, NHS 24, Glasgow, United Kingdom 
143  Division of Psychiatry, Centre for Clinical Brain Sciences, University of 
Edinburgh, Edinburgh, United Kingdom 
144  Psychiatry, Brigham and Women's Hospital, Boston, MA, USA 
145  Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, 
Germany 
146  Statistics, University of Oxford, Oxford, United Kingdom 
147  Department of Genetics, Harvard Medical School, Boston, MA, USA 
148  Psychiatry, Columbia University College of Physicians and Surgeons, New 
York, NY, USA 
149  Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA 
150  Genetic Cancer Susceptibility Group, International Agency for Research on 
Cancer, Lyon, France 
151  School of Psychology and Counseling, Queensland University of Technology, 
Brisbane, QLD, Australia 
152  Child and Youth Mental Health Service, Children's Health Queensland 
Hospital and Health Service, South Brisbane, QLD, Australia 
153  Child Health Research Centre, University of Queensland, Brisbane, QLD, 
Australia 
154  Estonian Genome Center, University of Tartu, Tartu, Estonia 
155  Discipline of Biochemistry, Neuroimaging and Cognitive Genomics (NICOG) 
Centre, National University of Ireland, Galway, Galway, Ireland 
156  Neuropsychiatric Genetics Research Group, Dept of Psychiatry and Trinity 
Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland 
157  Medical Genetics, University of British Columbia, Vancouver, BC, Canada 
158  Statistics, University of British Columbia, Vancouver, BC, Canada 
159  Institute of Neuroscience and Medicine (INM-1), Research Centre Jülich, 
Jülich, Germany 
160  DZHK (German Centre for Cardiovascular Research), Partner Site 
Greifswald, University Medicine, University Medicine Greifswald, Greifswald, 
Mecklenburg-Vorpommern, Germany 
161  Institute of Clinical Chemistry and Laboratory Medicine, University Medicine 
Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany 
162  Research/Psychiatry, Veterans Affairs San Diego Healthcare System, San 
Diego, CA, USA 
163  Institute of Health and Biomedical Innovation, Queensland University of 
Technology, Brisbane, QLD, Australia 
164  Department of Clinical Psychiatry, Psychiatry Clinic, Clinical Center University 
of Sarajevo, Sarajevo, Bosnia and Herzegovina 
165  Department of Neurobiology, Care sciences, and Society, Karolinska Institutet 
and Center for Molecular Medicine, Karolinska University Hospital, Stockholm, 
Sweden 
Coleman et al.  Supplement 
 
10 
166  Humus, Reykjavik, Iceland 
167  Mental Health Department, University Regional Hospital, Biomedicine Institute 
(IBIMA), Málaga, Spain 
168  Virginia Institute for Psychiatric & Behavioral Genetics, Virginia 
Commonwealth University, Richmond, VA, USA 
169  Solid Biosciences, Boston, MA, USA 
170  Outpatient Clinic for Bipolar Disorder, Altrecht, Utrecht, Netherlands 
171  Department of Psychiatry, Washington University in Saint Louis, Saint Louis, 
MO, USA 
172  Department of Biochemistry and Molecular Biology II, Institute of 
Neurosciences, Center for Biomedical Research, University of Granada, 
Granada, Spain 
173  Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New 
York, NY, USA 
174  Medicine, Psychiatry, Biomedical Informatics, Vanderbilt University Medical 
Center, Nashville, TN, USA 
175  Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA 
176  Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 
Stanford, CA, USA 
177  Rush University Medical Center, Chicago, IL, USA 
178  Department of Psychiatry, University of Groningen, University Medical Center 
Groningen, Groningen, Netherlands 
179  Scripps Translational Science Institute, La Jolla, CA, USA 
180  Department of Psychiatry and Psychotherapy, Medical Center of the 
University of Munich, Campus Innenstadt, Munich, Germany 
181  Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
Bethesda, MD, USA 
182  Behavioral Health Services, Kaiser Permanente Washington, Seattle, WA, 
USA 
183  Faculty of Medicine, Department of Psychiatry, School of Health Sciences, 
University of Iceland, Reykjavik, Iceland 
184  Div Mental Health and Addiction, Oslo University Hospital, Oslo, Norway 
185  NORMENT, University of Oslo, Oslo, Norway 
186  Institute of Health and Wellbeing, University of Glasgow, Glasgow, United 
Kingdom 
187  Psychiatry and the Behavioral Sciences, University of Southern California, 
Los Angeles, CA, USA 
188  Mood Disorders, PsyQ, Rotterdam, Netherlands 
189  Research Division, Federal Institute for Drugs and Medical Devices (BfArM), 
Bonn, Germany 
190  Centre for Addiction and Mental Health, Toronto, ON, Canada 
191  Neurogenomics, TGen, Los Angeles, AZ, USA 
192  College of Biomedical and Life Sciences, Cardiff University, Cardiff, United 
Kingdom 
193  Institute of Epidemiology and Social Medicine, University of Münster, Münster, 
Nordrhein-Westfalen, Germany 
194  Institute for Community Medicine, University Medicine Greifswald, Greifswald, 
Mecklenburg-Vorpommern, Germany 
195  Medical Genetics Section, CGEM, IGMM, University of Edinburgh, Edinburgh, 
United Kingdom 
Coleman et al.  Supplement 
 
11 
196  Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom 
197  Internal Medicine, Erasmus MC, Rotterdam, Zuid-Holland, Netherlands 
198  Roche Pharmaceutical Research and Early Development, Neuroscience, 
Ophthalmology and Rare Diseases Discovery & Translational Medicine Area, 
Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, 
Switzerland 
199  Psychiatry, Psychiatrisches Zentrum Nordbaden, Wiesloch, Germany 
200  Neuroscience Research Australia, Sydney, NSW, Australia 
201  Computational Sciences Center of Emphasis, Pfizer Global Research and 
Development, Cambridge, MA, USA 
202  Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, 
Canada 
203  Dalla Lana School of Public Health, University of Toronto, Toronto, ON, 
Canada 
204  Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, 
King's College London, London, United Kingdom 
205  Department of Mental Health, Johns Hopkins University Bloomberg School of 
Public Health, Baltimore, MD, USA 
206  Institute of Genetic Medicine, Johns Hopkins University School of Medicine, 
Baltimore, MD, USA 
207  NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental 
Health and Addiction, Institute of Clinical Medicine and Diakonhjemmet 
Hospital, University of Oslo, Oslo, Norway 
208  National Institute of Mental Health, Klecany, Czechia 
209  Department of Psychiatry, University of Münster, Münster, Germany 
210  Department of Psychiatry, University of Melbourne, Melbourne, VIC, Australia 
211  Department of Psychiatry and Addiction Medicine, Assistance Publique - 
Hôpitaux de Paris, Paris, France 
212  Paris Bipolar and TRD Expert Centres, FondaMental Foundation, Paris, 
France 
213  UMR-S1144 Team 1: Biomarkers of relapse and therapeutic response in 
addiction and mood disorders, INSERM, Paris, France 
214  Psychiatry, Université Paris Diderot, Paris, France 
215  Psychiatry, University of Pennsylvania, Philadelphia, PA, USA 
216  Centre for Integrative Biology, Università degli Studi di Trento, Trento, 
Trentino-Alto Adige, Italy 
217  Department of Psychiatry and Psychotherapy, Medical Center, University of 
Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany 
218  Division of Endocrinology, Children's Hospital Boston, Boston, MA, USA 
219  Centre for Affective Disorders, Institute of Psychiatry, Psychology and 
Neuroscience, London, United Kingdom 
220  Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA 
221  School of Medical Sciences, University of New South Wales, Sydney, NSW, 
Australia 
222  Department of Human Genetics, University of Chicago, Chicago, IL, USA 
223  Amsterdam Public Health Institute, Vrije Universiteit Medical Center, 
Amsterdam, Netherlands 
224  Biometric Psychiatric Genetics Research Unit, Alexandru Obregia Clinical 
Psychiatric Hospital, Bucharest, Romania 
225  Psychiatry, Kaiser Permanente Northern California, San Francisco, CA, USA 
Coleman et al.  Supplement 
 
12 
226  Medical Research Council Human Genetics Unit, Institute of Genetics and 
Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom 
227  Institute of Neuroscience and Physiology, University of Gothenburg, 
Gothenburg, Sweden 
228  INSERM, Paris, France 
229  Neuroscience Therapeutic Area, Janssen Research and Development, LLC, 
Titusville, NJ, USA 
230  Cancer Epidemiology and Prevention, M. Sklodowska-Curie Cancer Center 
and Institute of Oncology, Warsaw, Poland 
231  School of Psychology, The University of Queensland, Brisbane, QLD, 
Australia 
232  Research Institute, Lindner Center of HOPE, Mason, OH, USA 
233  Human Genetics Branch, Intramural Research Program, National Institute of 
Mental Health, Bethesda, MD, USA 
234  Division of Mental Health and Addiction, Oslo University Hospital, Oslo, 
Norway 
235  Division of Mental Health and Addiction, University of Oslo, Institute of Clinical 
Medicine, Oslo, Norway 
236  Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia 
237  Mental Health, Faculty of Medicine and Health Sciences, Norwegian 
University of Science and Technology - NTNU, Trondheim, Norway 
238  Psychiatry, St Olavs University Hospital, Trondheim, Norway 
239  Psychosis Research Unit, Aarhus University Hospital, Risskov, Denmark 
240  Munich Cluster for Systems Neurology (SyNergy), Munich, Germany 
241  University of Liverpool, Liverpool, United Kingdom 
242  Psychiatry and Human Genetics, University of Pittsburgh, Pittsburgh, PA, 
USA 
243  Mental Health Services in the Capital Region of Denmark, Mental Health 
Center Copenhagen, University of Copenhagen, Copenhagen, Denmark 
244  Division of Psychiatry, Haukeland Universitetssjukehus, Bergen, Norway 
245  Faculty of Medicine and Dentistry, University of Bergen, Bergen, Norway 
246  Human Genetics and Computational Biomedicine, Pfizer Global Research 
and Development, Groton, CT, USA 
247  College of Medicine Institute for Genomic Health, SUNY Downstate Medical 
Center College of Medicine, Brooklyn, NY, USA 
248  Psychiatry, Harvard Medical School, Boston, MA, USA 
249  Division of Clinical Research, Massachusetts General Hospital, Boston, MA, 
USA 
250  Department of Clinical Genetics, Amsterdam Neuroscience, Vrije Universiteit 
Medical Center, Amsterdam, Netherlands 
251  Department of Neurology and Neurosurgery, McGill University, Faculty of 
Medicine, Montreal, QC, Canada 
252  Montreal Neurological Institute and Hospital, Montreal, QC, Canada 
253  Department of Biomedical and NeuroMotor Sciences, University of Bologna, 
Bologna, Italy 
254  Faculty of Medicine, University of Iceland, Reykjavik, Iceland 
255  Department of Psychiatry, Hospital Namsos, Namsos, Norway 
256  Department of Neuroscience, Norges Teknisk Naturvitenskapelige Universitet 
Fakultet for naturvitenskap og teknologi, Trondheim, Norway 
Coleman et al.  Supplement 
 
13 
257  Child and Adolescent Psychiatry, Erasmus MC, Rotterdam, Zuid-Holland, 
Netherlands 
258  Psychiatry, Erasmus MC, Rotterdam, Zuid-Holland, Netherlands 
259  Department of Psychiatry, McGill University, Montreal, QC, Canada 
260  Dept of Psychiatry, Sankt Olavs Hospital Universitetssykehuset i Trondheim, 
Trondheim, Norway 
261  Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, 
IDIBAPS, CIBERSAM, Barcelona, Spain 
262  Division of Epidemiology, New York State Psychiatric Institute, New York, NY, 
USA 
263  Department of Clinical Medicine, University of Copenhagen, Copenhagen, 
Denmark 
264  Biochemistry and Molecular Biology, Indiana University School of Medicine, 
Indianapolis, IN, USA 
265  Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel 
Hill, NC, USA 
266  Department of Medical & Molecular Genetics, King's College London, London, 
United Kingdom 
267  Department of Psychiatry, Indiana University School of Medicine, 
Indianapolis, IN, USA 
268  Department of Genetics, University of North Carolina at Chapel Hill, Chapel 
Hill, NC, USA 
  
† Deceased  
Coleman et al.  Supplement 
 
14 
Supplementary Note 
Relationship between these analyses and recent depression analyses from the UK 
Biobank 
The PGC GWAS of major depression included data from the first 150,000 UK 
Biobank individuals whose genotypic data was released (1). Depression GWAS in 
the full UK Biobank cohort have since been published, including both broad and 
narrow definitions (2). The broad depression GWAS was meta-analysed with data 
from the PGC publication (3). We conducted a further meta-analysis of PGC and UK 
Biobank major depressive disorder data, using data from the online mental health 
phenotyping, including questions derived from the Composite International 
Diagnostic Interview – Short Form (4, 5). This phenotype has good concordance with 
direct clinical assessments of major depressive disorder and can be considered a 
major depressive disorder phenotype, compared to the less specific broad 
depression phenotype used by Howard et al (3, 6, 7). The effects on GWAS of using 
different depression phenotypes from the UK Biobank is investigated in depth 
elsewhere (8). We compare our results with those from Howard et al where 
appropriate (3). 
Supplementary Methods 
Participants 
The PGC MDD cohort consists of an anchor set of 29 cohorts (16,823 cases 
and 25,632 controls), with case individuals meeting international consensus criteria 
(DSM-IV, ICD-9, or ICD-10) for a lifetime diagnosis of major depressive disorder 
using structured diagnostic instruments. Six additional cohorts (118,635 cases and 
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319,269 controls) were drawn from broader population-based studies, and cases 
met criteria through self-report or responses to structured diagnostic instruments. 
Controls in most samples were screened for the absence of lifetime psychiatric 
disorders. All participants were of Western European ancestries. Individuals from the 
anchor cohort meet criteria for major depressive disorder. However, the additional 
cohorts include individuals who self-reported their diagnosis, and might not have met 
criteria for major depressive disorder in a clinical setting. In particular, these 
additional cohorts included data from 23andMe, where case participants were 
defined by a positive endorsement of a single question "Have you ever been 
diagnosed with clinical depression?" (or a different version of this question with 
similar phrasing) (9). These participants self-reported a professional diagnosis of 
depression, rather than being ascertained via a direct examination of all criteria for 
major depressive disorder. As such, it was considered more appropriate to refer to 
these individuals as having major depression, rather than major depressive disorder 
(1). 
The PGC BD cohort consists of 32 studies (20,352 cases and 31,358 
controls) of Western European ancestries. Case individuals were required to meet 
international consensus criteria for a lifetime diagnosis of bipolar disorder using 
structured diagnostic instruments. Controls in most samples were screened for the 
absence of lifetime psychiatric disorders. 
In the UKB MDD cohort, participants were defined as cases if they met criteria 
based on questions derived from the Composite International Diagnostic Interview 
(CIDI). Participants were excluded if they self-reported previous diagnoses of 
schizophrenia (or other psychoses) or bipolar disorder. Controls were excluded if 
they self-reported any mental illness, reported taking any drug with an 
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antidepressant indication, had previously been hospitalised with a mood disorder or 
met previously-defined criteria for a mood disorder (Supplementary Table 1) (10).  
Quality control and imputation of UK Biobank data was performed centrally 
and is described elsewhere (11). Additional quality control was performed and is 
described in full elsewhere (5). In brief, participants were limited to unrelated 
individuals (KING correlation coefficient < 0.044 with all pairs, equivalent to removing 
all third degree-or-closer relatives) from probable Western European ancestries with 
good quality genotype data (passed Affymetrix and central UK Biobank quality 
assurance processes, genotyping call rate > 98%, concordant genotypic and 
phenotypic sex). Genome-wide association analyses (GWAS) of each UKB cohort 
were performed in BGenie v1.2, limited to variants with minor allele frequency (MAF) 
> 0.01 that were genotyped or imputed with confidence (IMPUTE2 INFO score > 0.4) 
(11, 12). All GWAS included six genotypic principal components (derived from the 
Western European ancestries subset of the UKBiobank using flashpca2) (13) and 
factors of genotyping batch and assessment centre as covariates to control for batch 
effects and population stratification. BGenie performs linear regressions on 
phenotypes residualised for covariates - as such, the resulting beta effect sizes (for 
all UKB analyses) were converted to odds ratios for meta-analysis using LMOR (14). 
Standard errors for the odds ratios were calculated by transforming the BGenie p-
value to a Z score and dividing log(odds ratio) by Z (15). 
Use of MAF > 0.05 as a cutoff 
All summary statistics were limited to variants with MAF > 0.05. This was 
chosen because previous analyses of the BD2 subtype suggested that including 
lower MAF variants may bias SNP-based heritability estimates (16). Specifically, the 
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BD2 subtype comprises multiple small cohorts, some with unbalanced case/control 
numbers. Consequently, potentially spurious effects in a single study can drive 
results for low-frequency variants. We therefore chose to remove lower frequency 
variants from all analyses in this paper. 
Population prevalences 
 SNP-based heritability estimates were transformed to the liability scale 
assuming that the combined population prevalence between major depressive 
disorder and bipolar disorder is the sum of the disorder prevalences. Specifically, we 
assumed a population prevalence of 15% for combined MDD, 1% for PGC BD, and 
thus 16% for MOOD. Further estimates were made for the lower bounds of 
prevalence and upper bounds of prevalence for comparison. Namely, we set lower 
bounds of population prevalence at 10% for combined MDD, 0.5% for PGC BD and 
10.5% for MOOD, and upper bounds at 20%, 2% and 22% for combined MDD, PGC 
BD and MOOD respectively. 
Definition of non-overlapping N 
As some analyses (particularly LD score regression) use the total number of 
subjects in the analysis for calculations, a "non-overlapping N" was estimated for 
each meta-analysis, using the following equation (derived from the equation 
describing the genetic covariance intercept in LD Score) (17): 
Non-overlapping N = N1 + (N2 - (gcov_int * √N1N2)) 
where N1 is the cohort size of the larger component part of the meta-analysis, N2 is 
the same for the smaller cohort and gcov_int is the genetic covariance intercept from 
the calculation of genetic correlation between the component parts in LD Score. This 
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method can be extended to the meta-analysis of three cohorts in a two-step process 
(calculating a non-overlapping N for cohorts one and two, and then the non-
overlapping N for the meta-analysis of the combined one-two cohort with cohort 
three). In the case of MOOD herein, the non-overlapping N was calculated as if 
meta-analysing PGC MDD and PGC BD followed by UKB MDD; and as if meta-
analysing PGC MDD and UKB MDD followed by PGC BD. The average of the two 
results was taken as the non-overlapping N. Note that this equation implicitly 
assumes that the phenotypic correlation between the traits of interest in the 
overlapping samples is 1 (which is reasonable in this instance). Note also that the 
resulting non-overlapping N is underestimated in the presence of shared 
confounding between the cohorts (such as through population stratification) (18). 
Comparison of METACARPA with meta-analysis of independent cohorts 
We contributed individuals from the UK Biobank to PGC MDD, and so were 
able to define the overlap between PGC MDD and UKB MDD (3,087 cases and 
5,128 controls, representing 10% and 8% of UKB MDD respectively). To examine 
the robustness of meta-analysis using overlapping cohorts in METACARPA, we re-
ran UKB MDD excluding these overlapping individuals and then meta-analysed the 
results with PGC MDD using inverse variance weighted meta-analysis in METAL. 
We calculated genetic correlations between the results using LDSC, and calculated 
Pearson's correlations between the betas and p-values of the two analyses. Results 
of these analyses were highly consistent (betas r = 0.99, p-values r = 0.98, LDSC rg 
= 1), suggesting METACARPA can adjust adequately for overlap between cohorts. 
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Definition of GWAS loci 
GWAS results were clumped using PLINK1.9, assigning nominally-significant 
(p < 10-4) variants to a clump if they were in linkage disequilibrium (r2 > 0.1 in 
unrelated non-Finnish European participants from 1000 Genomes project) with a 
variant with a lower p-value lying within 3Mb (19, 20). Non-Finnish Europeans were 
used for the LD reference panel because they were the best match for the 
participants included in this analysis, who were of predominantly Western European 
ancestries. Loci were declared genome-wide significant if a variant in the locus 
reached the conventional threshold for genome-wide significance (p = 5 x 10-8). 
Results were visualised using FUMA, including mapping the loci to potentially 
affected genes through expression quantitative trait loci (eQTLs) and chromatin 
contact sites in brain tissues or neural progenitor cells (21). 
All genomic loci reaching genome-wide significance in at least one analysis 
were combined for annotation. Where loci from different GWAS overlapped, they 
were combined into a single locus ranging from the minimum base position from any 
of the constituent loci to the maximum. Annotation was performed using 
RegionAnnotator version 1.63 (https://github.com/ivankosmos/RegionAnnotator), 
which includes data from: the NHGRI-EBI GWAS Catalog; OMIM; GENCODE 
genes; genes previously implicated in autism and in intellectual disability; copy-
number variants previously implicated in psychiatric disorders; and mouse knockout 
phenotypes. Results from the GWAS Catalog module of RegionAnnotator were 
filtered to include only variants reaching genome-wide significance. Where multiple 
variants are listed as significant from a previous GWAS of a specific phenotype, only 
the variant with the lowest p-value is reported. Results from the GWAS Catalog 
module were supplemented by direct query of the NHGRI-EBI GWAS Catalog for 
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each region (data from 2018-11-05), lookup of top SNPs in http://atlas.ctglab.nl, and 
manual assessment of psychiatric and behavioural GWAS not yet listed in the 
NHGRI-EBI GWAS Catalog.  
Relationship between meta-analyses (hierarchical clustering) 
The relationship between the loci identified in the meta-analyses (MOOD, 
combined MDD) and the constituent analyses (PGC MDD, UKB MDD, PGC BD) was 
assessed using a hierarchically-clustered heatmap, with the 2014 PGC 
schizophrenia analysis (SCZ) included for comparison (22). For the purpose of this 
comparison, an index SNP was selected for each locus (the variant with the lowest 
p-value that was common to all four analyses) to obtain the direction of effect in each 
analysis. Index SNP p-values were converted to -log10(p-value). If the ORindex < 1 in a 
given analysis, the log10(p-value) was used in place of the -log10(p-value). A 
hierarchically-clustered heatmap was then generated using the default options of the 
heatmap.2 function of the gplots package in R v1.4.1 (complete clustering on the 
Euclidean distance between vectors) with clustering performed separately for rows 
and for columns (23, 24). 
Hierarchical clustering of genetic correlations between subtypes, and extension to 
examine relationships with related traits 
Genetic correlations between the major depressive disorder and bipolar 
disorder subtypes were hierarchically clustered using the method described above. 
In addition, we included results from six external GWAS relevant to mood disorders. 
We examined relationships with anxiety disorders (correlated with depressive 
phenotypes), schizophrenia (correlated with bipolar disorder), and ADHD (showed 
differing genetic correlations with PGC MDD and PGC BD) (22, 25, 26). We also 
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examined subjective wellbeing, which may reflect positive mood, and included 
measures of specific aspects of wellbeing, namely eudaimonic wellbeing (feeling life 
has meaning) and hedonic wellbeing (feeling happy) (27, 28). For hierarchical 
clustering only, the sign of genetic correlations with the three wellbeing phenotypes 
were reversed so that positive effect sizes meant poor outcomes for all phenotypes. 
We concluded that the genetic correlations between subtypes of major 
depressive disorder and bipolar disorder were indicative of a genetic mood disorder 
spectrum. To validate this conclusion, we performed a principal component analysis 
of the genetic correlation matrix as used for hierarchical clustering above (that is, 
including the six external GWAS with correlations with the wellbeing phenotypes 
reversed). Principal component analysis was performed using the prcomp function 
from base R, and using plot3D (https://cran.r-project.org/package=plot3D) for 
visualisation (23). 
Conditional and reversed-effect analyses 
Analyses were performed to understand which genomic loci are shared or 
distinct between the disorders, using mtCOJO, an extension of the GSMR method 
implemented in GCTA (29, 30). mtCOJO adjusts the results of a genome-wide 
association analysis, conditioning on the effects of a set of significantly associated, 
independent variants from a second set of summary statistics (a putative 
instrumental variable). This putative instrumental variable is also used as a proxy for 
the trait of interest to infer causal direction in GSMR analyses. The effect size 
estimated by this method is robust to confounding caused by genetic or 
environmental effects shared between the studies analysed, assuming these are 
uncorrelated with the instrumental variable. mtCOJO adjusts for sample overlap (i.e. 
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the same individuals being present in both datasets) using the genetic covariance 
intercept from LD score regression (29, 31). 
Conditional analyses in mtCOJO were performed on combined MDD 
conditional on PGC BD (MDDcBD), and on PGC BD conditional on combined MDD 
(BDcMDD). Variant selection for conditioning was performed with the default settings 
in mtCOJO, clumping using the UK Biobank dataset, and selecting at least ten 
variants with p<5x10-8, which were not in linkage disequilibrium (r2 < 0.05) with a 
variant with a lower p-value, and which did not show evidence of pleiotropy (passed 
the HEIDI-outlier analysis, threshold 0.01) (29). As down-sampled MDD had only 
eight variants with p<5x10-8, conditional analyses and GSMR were not performed 
using this meta-analysis. Similarly, BDcMDD had only six variants passing genome-
wide significance, so GSMR analyses with BDcMDD as the exposure were not 
possible. Results were clumped in PLINK using the procedure described above. 
Genetic correlations were compared between combined MDD and MDDcBD, and 
between PGC BD and BDcMDD, first using a z-test to identify putative differences (p 
< 0.05), and then formally testing by applying a block-jackknife (described below). A 
conservative Bonferroni correction was used to determine significance (p < 1.27x10-
4, approximate correction for 414 tests) (32–34). 
A further analysis was performed to identify loci with opposite directions of 
effect between combined MDD and PGC BD. For this analysis, the direction of 
effects for the PGC BD analysis was reversed, and the MOOD meta-analysis 
repeated as described in the main text. 
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GSMR 
GSMR uses the HEIDI test to remove pleiotropic variants from the instrument 
variable set. All analyses were run using the default settings in GSMR, assuming at 
least ten linkage-independent (r2 < 0.05) significant (p<5x10-8) variants pass the 
HEIDI test (threshold p<0.01). 
Comparing two genetic correlations using jackknife and LDSC 
Let there be four phenotypes A, B, C, and D. The goal is to compare the 
genetic correlation between A and B to the genetic correlation between C and D. 
Global estimates of these correlations can be computed using the LDSC software 
and will be noted r(A,B) and r(C,D). The same software can output jackknife delete 
values for genetic covariance: G(A,B), G(C,D), as well as for heritability: H(A,B) and 
H(C,D). These jackknife delete values are estimated by excluding blocks of values 
(here, number of blocks n = 200). The n-dimensional vectors G(A,B), G(C,D), H(A,B) 
and H(C,D) can be used to generate genetic correlation delete values R(A,B) and 
R(C,D). The difference between the global estimates r(A,B) and r(C,D) is d(AB,CD), 
and the difference between the vectors R(A,B) and R(C,D) is D(AB,CD). The global 
genetic correlation difference d(AB,CD) and the delete values D(AB,CD) are used to 
compute jackknife pseudovalues. The ith pseudovalue is 
 
𝑃 𝐴𝐵,𝐶𝐷 𝑛 𝑑 𝐴𝐵,𝐶𝐷 𝑛 1 ∗ 𝐷 𝐴𝐵,𝐶𝐷  
 
The mean and variance of the jackknife pseudovalues are 
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𝑚 𝐴𝐵,𝐶𝐷
1
𝑛
𝑃 𝐴𝐵,𝐶𝐷  
𝑣 𝐴𝐵,𝐶𝐷
1
𝑛 1
𝑃 𝐴𝐵,𝐶𝐷 𝑚 𝐴𝐵,𝐶𝐷  
 
The jackknife estimate of the difference between the two correlations m(AB,CD) can 
then be compared to test H0 : θ = θ0 (θ0 = 0 for no difference between genetic 
correlations), and a p-value can be derived from the z statistic: 
 
𝑧 𝐴𝐵,𝐶𝐷
𝑚 𝐴𝐵,𝐶𝐷 𝜃
1/𝑛 𝑣 𝐴𝐵,𝐶𝐷
 
Estimating local SNP-based heritability and genetic covariance in HESS 
Local estimates of SNP-based heritability and genetic correlation were 
obtained using HESS v0.5.3b (35, 36). All analyses used the reference panel 
provided with the software (1000 Genomes Project European individuals) and 
previously defined blocks of the genome in linkage equilibrium, with 50 eigenvectors 
for inverting the LD matrix and a minimum eigenvalue cutoff of 1 (37, 38). Overlap 
between cohorts was calculated consistent with the calculation of non-overlapping N 
(see above), assuming overlapping individuals had a phenotypic correlation of 1 (that 
is, overlapping individuals were controls in both studies). Local heritability estimates 
were calculated for all meta-analyses, component GWAS and subtypes. Local 
genetic covariance was calculated between combined MDD and PGC BD, between 
MOOD and down-sampled MOOD, and between all of the major depressive disorder 
and bipolar disorder subtype pairwise.  
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Gene-wise and gene-set enrichment analyses 
For all analyses, gene-wise p-values were calculated as the aggregate of the 
mean and smallest p-value across all SNPs annotated to Ensembl gene locations 
using MAGMA v1.06 (using the build 37 reference supplied on the MAGMA website) 
(39). SNPs were assigned to genes if they lay between 35kb upstream and 10kb 
downstream of the gene location (40). MAGMA accounts for possible confounders 
such as gene size, gene density, linkage disequilibrium and minor allele count. The 
threshold for genome-wide significance was defined at p < 2.6x10-6 (Bonferroni 
correction for the 19,041 genes tested). Genes passing genome-wide significance 
were defined as coming from the same locus if they lay within 100kb of each other, 
or if they overlapped a locus from the single variant analysis. Gene set analysis was 
performed in MAGMA for 13,567 gene sets. Significance was set at a Bonferroni-
corrected threshold of p = 5.34x10-6 for 9,361 effectively independent tests within 
each analysis.  
Gene set analysis was performed for all analyses. A gene set matrix P was 
generated with elements Pg,p = 1 if gene g was in set p and Pg,p = 0 otherwise. 
Association between gene set membership and gene-wise z-scores was computed 
using MAGMA. 13,567 gene sets were drawn from OpenTargets (downloaded 
January 2017) (41), GO ontologies, canonical gene sets drawn from MSigSB v5.2 
C2 and C5 datasets (42), and biological gene sets related to psychiatric disorders 
described in various scientific publications. There is considerable overlap of genes 
between gene sets (within and between sources). Gene sets that overlapped entirely 
were treated as a single gene set in analyses. The effective number of gene sets 
tested was defined as the number of principal components accounting for 99.5% of 
explained variance in the gene set similarity matrix, obtained by computing the 
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Tanimoto similarity between gene sets. This results in a Bonferroni-corrected 
threshold of p = 5.34x10-6 for 9,361 effectively independent tests for each matrix.  
Tissue and single-cell enrichment analyses 
Further analyses were performed to assess the enrichment of associated 
genes with expression-specificity profiles from tissues (version 7 data from the 
Genotype-Tissue Expression project) and broadly-defined ("level 1") and narrowly-
defined ("level 2") cell-types (Karolinska Institutet mouse brain single-cell RNA 
sequencing superset) (43, 44). Analyses were performed in MAGMA following 
previously described methods with minor modifications (44). Briefly, for the single 
cell data set (44), gene expression for each cell type was scaled to 1,000,000 unique 
molecular identifiers prior to computing specificity scores. Specificity scores are 
defined as the proportion of the total expression of a specific gene found in a given 
cell type. For the GTEx dataset, transcripts per million (TPM) were transformed to 
log2(TPM +1) prior to computing specificity scores. For each tissue or cell-type, the 
specificity scores were then rank-transformed to a standard normal distribution using 
the rntranform function from the GenABEL R package (45). The standard normalised 
specificity scores were then regressed on gene-wise association in the meta-
analysis, defined as the mean p-value across all SNPs assigned to the gene. 
Multiple-testing correction was applied using Bonferroni-correction within each 
analysis. 
Association with predicted brain tissue gene expression 
Variant-level meta-analysis results were used to predict gene expression 
using S-PrediXcan and genomic and transcriptomic reference data from the thirteen 
brain regions assayed in the GTEx project (version 7) (43, 46). Associations were 
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calculated between these predicted gene expression levels and each meta-analysed 
phenotype. Significance was set at 8.5x10-8, the Bonferroni correction for 586,469 
tests (45,113 genes across 13 tissues) as in the original S-PrediXcan publication 
(46). Genes were defined as coming from the same locus following the approach 
described for MAGMA analyses. 
Polygenic risk score prediction of UKB subtypes using PGC BD summary statistics 
In order to determine if the recurrent major depressive disorder subtype 
(rMDD) was genetically more similar to PGC BD than were other major depressive 
disorder subtypes (single episode major depressive disorder, sMDD;and 
subthreshold depression, subMDD), polygenic risk score analyses were performed 
using PRSice2 (47). PGC BD results were used as the base analysis to produce 
polygenic risk scores (PRS) in the genotyped data from the UKB sample, and these 
were then compared across the major depressive disorder subtypes using logistic 
regression (including the covariates described above for the UKB GWAS). PRS were 
derived using linkage-independent (r2 < 0.1, ± 250kb) variants at seven p-value 
thresholds from the PGC BD data (pT = 0.001, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5). 
Correction for multiple-thresholding was performed by using 20000 permutations 
(using the permutation function in PRSice2) to produce an empirical p-value 
(minimum possible empirical p = 5x10-5). Variance explained was initially calculated 
as Nagelkerke pseudo-R2 (using the fmsb package in R) and was subsequently 
converted to liability scale using http://cnsgenomics.com/shiny/abc/ (48, 49). 
Population prevalences for each subtype were set as follows: rMDD = 0.05; sMDD = 
0.15; subMDD = 0.2. The population prevalence for each comparison was then 
calculated as each prevalence divided by the summed prevalence to give the 
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following: rMDD vs sMDD = 0.25 (that is, 0.05 / [0.05+0.15] ); rMDD vs subMDD = 
0.2; sMDD vs subMDD = 0.429. 
Supplementary Results 
Conditional analyses 
We performed analyses of combined MDD conditioning on PGC BD 
(MDDcBD). Diminished effects (shrinkage of the odds ratio shrinkage towards 1) 
were observed in 51/63 loci reaching genome-wide significance in combined MDD, 
suggesting most loci significantly associated with combined MDD have the same 
direction of effect in PGC BD (Supplementary Table 13). Results from the reverse 
analysis (PGC BD conditioned on combined MDD: BDcMDD) support this 
conclusion, with 14/19 associated loci from PGC BD showing a diminished effect 
(Supplementary Table 13). 
The SNP-based heritability of the conditional analyses showed reduced 
estimates compared to the respective main analyses (MDDcBD: 7%, combined 
MDD: 9%, BDcMDD: 17%, PGC BD: 20%, Supplementary Table 2). Genetic 
correlations for MDDcBD mirror those for combined MDD, except that genetic 
correlations with schizophrenia (and related analyses, such as the schizophrenia-
bipolar disorder meta-analyses) were significantly smaller (Supplementary Figure 12, 
Supplementary Tables 5 and 14) (22, 50). The genetic correlations from BDcMDD 
were similar to PGC BD, with significant reductions only with studies of depression 
and anxiety (Supplementary Tables 15 and 15) (26, 51, 52).  
In addition to conditional analyses, we reversed the observed effects from 
PGC BD and meta-analysed with combined MDD. 32 loci were significant in the 
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resulting MOOD BD Reversed analysis (Supplementary Table 3). All loci were 
strongly associated with combined MDD (max p = 2x10-7), 27 passing genome-wide 
significance, compared with only one locus passing significance in PGC BD. 19 loci 
showed consistent direction of effect between combined MDD and PGC BD, 
indicating that these loci were driven by strong associations with combined MDD, 
rather than having a differing effect on major depressive disorder than on bipolar 
disorder. The smallest p-value observed in PGC BD for any of the 13 loci with 
differing directions of effect was p=6x10-6, for locus Rev2 on chromosome 7. This 
locus contains the CTTNBP2 gene, rare variants in which have suggestive evidence 
for implication in autism spectrum disorder (53). 
Down-sampled reversed analyses yielded three loci passing genome-wide 
significance (Supplementary Table 3). All of these loci passed genome-wide 
significance in down-sampled MDD and had shared directions of effect between 
PGC BD and down-sampled MDD, indicating these loci do not have a differing effect 
on major depressive disorder than on bipolar disorder. 
Tissue and cell-type expression specificity analyses showed high consistency 
between the main and the conditional analyses (Supplementary Tables 9-11). All 
brain tissues were enriched in both conditional analyses. In cell-type analyses, 
neuroblasts, adult dopaminergic neurons, embryonic GABAergic and midbrain 
nucleus neurons were significantly enriched in MDDcBD and not in BDcMDD. 
Conversely, medium spiny neurons (as well as both sets of pyramidal cells and the 
striatal interneurons) were significantly enriched in BDcMDD and not in MDDcBD. 
GSMR analyses also showed high consistency between the main and the 
conditional analyses, although these analyses were limited because BDcMDD had 
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too few variants with p<5x10-8 and so could only be used as an outcome, not an 
exposure, in GSMR analyses (Supplementary Figure 13, Supplementary Tables 12). 
MDDcBD had no significant relationship with PGC BD (nor BDcMDD with combined 
MDD), suggesting that conditioning was effective at removing the bidirectional 
relationship seen between combined MDD and PGC BD. Otherwise, results 
observed for combined MDD were also observed for MDDcBD, except that the 
positive association of major depressive disorder on CAD was attenuated and did 
not pass significance in MDDcBD. Results observed for PGC BD (as an outcome) 
were also observed for BDcMDD. 
Gene-wise and gene set analyses 
Gene-wise association analyses in MAGMA identified 361 genes associated 
with the MOOD phenotype at p < 2.6x10-6 (Supplementary Table 16). Associated 
genes were distributed across 120 loci, including 47 of the loci identified in MOOD. 
However, proximity is only a weak indication of the association of a gene with a trait 
(54). More evidence is provided by the convergence of brain-derived eQTL and 
chromatin contact data from a locus onto a single gene (Supplementary Figures 14-
33 - note no figures are provided for chromosomes 8 or 21, as there are no 
significant loci on these chromosomes). In MOOD, such evidence suggested 
significant loci may act on NEGR1 (loci 2 and 3), RSRC1 (locus 14), TMEM161B 
(locus 18), LHX2 (locus 41), SOX5 (locus 53), LACC1 (locus 56), PCDH8 (locus 57) 
and ZC2HC1C (locus 61). However, diverse eQTL and chromatin contacts were 
observed at many of these loci, suggesting these associations may act through other 
genes as well. 
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Results from gene set analysis were generally similar between combined 
MDD and PGC BD, and in each of the conditional analyses (Supplementary Table 
17). Gene sets significantly enriched across all analyses included genes previously 
implicated in schizophrenia, targets of the RNA splicing proteins CELF4 and 
RBFOX1/RBFOX3, loss-of-function intolerant (pLI09) genes, and genes with 
products potentially involved in synaptic processes (Supplementary Table 17). 
Certain gene sets were enriched in one disorder only - for example, RBFOX2 targets 
were significantly enriched in combined MDD, but not in PGC BD. In contrast, gene 
sets annotated as mutation-intolerant (constrained and genic intolerance RVIS) were 
significantly enriched in PGC BD but not combined MDD. In the conditional analyses, 
results for combined MDD and MDDcBD were similar, with significantly associated 
gene sets falling into broad categories of psychiatrically associated, 
neurodevelopmental, and anthropometric gene sets (Supplementary Table 17). 
Fewer significant gene sets were observed in BDcMDD than in PGC BD, but 
included mutation-intolerant gene sets (Supplementary Table 17).  
Local SNP-based heritability and genetic covariance 
Genome-wide SNP-based heritability estimates on the observed scale were 
similar between LDSC and HESS for all main meta-analyses (Supplementary Table 
18). For both MOOD and combined MDD, local SNP-based heritability was 
significantly >0 in the region overlapping loci 2 and 3 (near NEGR1), and for multiple 
regions comprising locus 25 (the major histocompatibility locus; p < 2.94x10-5, 
Bonferroni correction for 1703 LD-independent regions). No regions had significant 
local SNP-based heritability for PGC BD. Combined MDD and PGC BD were 
significantly genetically correlated (0.29, compare 0.35 from LDSC; Supplementary 
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Table 19), but no regions had local genetic covariance that significantly differed from 
0 (p > 2.94x10-5).  
The observed SNP-based heritability of down-sampled MOOD from HESS 
was 11% (compare LDSC 8%; Supplementary Tables 2 and 18). Only one region, 
part of locus 25, had local SNP-based heritability significantly >0. One region on 
chromosome 10 had local SNP-based heritability significantly >0 in down-sampled 
MDD. However, this is probably a false positive, there are no variants significantly 
associated with down-sampled MDD in the region. In addition, this region 
encompasses the centromere of chromosome 10, which may result in the LD 
structure of the region being specified incorrectly. 
Genetic correlations of mood disorder subtypes 
Genetic correlations between the bipolar disorder and major depressive 
disorder subtypes suggest a spectrum of genetic relationships between major 
depressive disorder and bipolar disorder, with BD2 bridging the two disorders 
(Supplementary Figure 34). Adding in six external phenotypes resulted in two 
clusters, with two sets of intermediate phenotypes (Supplementary Table 10, 
Supplementary Figures 35-40). Major depressive disorder subtypes cluster with 
anxiety disorders and the wellbeing spectrum, albeit with negative genetic 
correlations with wellbeing. The relationship of the wellbeing spectrum with 
depressive disorders was captured more effectively by hedonic rather than 
eudaimonic wellbeing - however, neither of these wellbeing subtypes clustered with 
depressive disorders, reinforcing previous conclusions that wellbeing is 
multidimensional (55). In contrast, schizophrenia clusters with schizoaffective bipolar 
disorder and bipolar disorder type 1, consistent with the greater genetic similarity of 
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these subtypes to schizophrenia (16, 56). ADHD has a moderate genetic correlation 
with bipolar disorder type 2, but not with the other bipolar disorder subtypes, arguing 
that the weaker genetic correlation between ADHD and bipolar disorder (compared 
to major depressive disorder) is specific to type 1 bipolar disorder. 
Principal component analysis identified three principal components 
accounting for >90% of the variance in the genetic correlation matrix (Supplementary 
Figure 41). The first principal component accounted for 59% of the variance, and 
described the spectrum as proposed above, separating the cluster of schizophrenia, 
schizoaffective bipolar disorder, and bipolar disorder type 1 from the cluster of the 
depressive disorders, with bipolar disorder type 2 and ADHD intermediate between 
the two. The second (21% variance explained) principal component separated the 
eudaimonic and hedonic wellbeing phenotypes from the other phenotypes, and the 
third principal component (12% variance explained) separated ADHD from the other 
phenotypes (Supplementary Figure 41). 
Estimates of local heritability (Supplementary Table 18) and genetic 
covariance (Supplementary Table 19) were calculated in HESS to assess whether 
specific regions of the genome were shared or distinct between subtypes. However, 
with the exception of BD1 and rMDD, SNP-based heritability estimates on the 
observed scale from HESS did not differ significantly from 0 (BD1 = 33%; BD2 = 3%; 
SAB = 0.4%; rMDD = 9%; sMDD = 0%; subMDD = 0.1%). This most likely resulted 
from the small cohort size of the subtype analyses, which results in a downward bias 
in SNP-based heritability estimation in HESS (36). No regions had significant local 
SNP-based heritability for any of the subtypes (all p > 2.94x10-5, Bonferroni 
correction for 1703 LD-independent regions). BD1 and rMDD were genetically 
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correlated (0.36, compare 0.31 from LDSC; Supplementary Table 10), but no region 
had a genetic covariance significantly >0 (all p > 2.94x10-5). 
Genetic correlations of PGC MDD and PGC BD with mood disorder subtypes 
The genetic correlation of PGC MDD and BD2 was stronger than those with 
BD1 (Δrg [difference between rg estimates] = 0.39, p = 1x10-4) and with SAB (Δrg = 
0.52, p = 2x10-5), but the genetic correlations with BD1 and with SAB were not 
significantly different (Δrg = 0.14, p = 0.05). PGC BD had a stronger genetic 
correlation with rMDD than with subMDD (Δrg = 0.27, p = 3x10-5), but the genetic 
correlation between PGC BD and sMDD was not significantly different to those with 
rMDD (Δrg = -0.07, p = 0.5) nor with subMDD (Δrg = 0.20, p = 0.009). 
Results from PGC MDD + subtype meta-analyses 
Bipolar disorder subtypes 
64 loci reached genome-wide significance across the meta-analyses between 
PGC MDD and the bipolar disorder subtypes (MDD-BD1, MDD-BD2, and MDD-SAB; 
Supplementary Table 3). Of these, 54 also reached significance in MOOD. The ten 
remaining loci were significant in MDD-BD2 alone (four loci), in MDD-BD2 and in 
MDD-SAB (three), in MDD-BD1 and in MDD-BD2 (one), in MDD-BD1 (one), and in 
MDD-SAB (one). Gene-wise association analyses in MAGMA identified 272 genes 
associated at p < 2.6x10-6 in at least one of the meta-analyses (Supplementary 
Table 16). Associated genes were distributed across 86 loci, including 44 of the loci 
identified by at least one single variant meta-analysis. 
Heritability estimates for the meta-analyses between PGC MDD and the 
bipolar disorder subtypes were all very similar, ranging from 8-10% (assuming a 
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lower bound of population prevalence of 10.5%, and an upper bound of 22%; 
Supplementary Table 2). Genetic correlations with previously-published traits were 
broadly similar across the different meta-analyses, and mirrored those from the main 
MOOD meta-analysis (psychiatric and behavioural, reproductive, and 
sociodemographic traits; Supplementary Table 5). 
Major depressive disorder subtypes 
65 loci reached genome-wide significance across the meta-analyses between 
PGC MDD and the major depressive disorder subtypes (MDD-rMDD, MDD-sMDD, 
and MDD-subMDD; Supplementary Table 3). Of these, 52 also reached significance 
in the MOOD analysis - the remaining 13 loci were significant in MDD-rMDD alone 
(four loci), in MDD-subMDD alone (four), in MDD-rMDD and MDD-subMDD (three), 
in all three analyses (one) and in MDD-sMDD and MDD-subMDD alone (one). Gene-
wise association analyses in MAGMA identified 261 genes associated at p < 2.6x10-6 
in at least one of the meta-analyses (Supplementary Table 16). Associated genes 
were distributed across 93 loci, including 45 of the loci identified by at least one 
single variant meta-analysis. 
Heritability estimates for the meta-analyses between PGC MDD and the major 
depressive disorder subtypes were all similar, ranging from 7-10% (assuming a 
lower bound of population prevalence of 10%, and an upper bound of 20%), 
although estimates for MDD-rMDD were slightly higher than those for MDD-sMDD 
and MDD-subMDD (Supplementary Table 2). Genetic correlations with previously-
published traits were broadly similar across the different meta-analyses, and 
mirrored those from the main MOOD meta-analysis (psychiatric and behavioural, 
reproductive, and sociodemographic traits; Supplementary Table 5).  
Coleman et al.  Supplement 
 
36 
Gains in discovery through adding individuals with different mood disorder diagnoses 
The PGC MDD analysis was meta-analysed with PGC BD and UKB MDD 
cohorts and with the subtypes of both bipolar disorder and major depressive 
disorder. The relative increase in mood-disorder associated loci obtained by adding 
1000 effective cases from different definitions to the PGC MDD GWAS was 
assessed. Effective cases were defined as half of the effective N (2 / [[1+Cases] + 
[1+Controls]]) (57). The resultant increase in locus discovery per 1000 effective 
cases of UKB MDD, PGC BD and each subtype is described in Supplementary 
Table 20. With the exception of SAB (the power of which is very low), meta-analysis 
with PGC MDD resulted in an increased number of loci in all cases, with BD2 
providing the most additional loci per 1000 effective cases (0.67). BD1 cases 
provided a similar amount of additional loci to rMDD (0.5 vs 0.51), and both out-
performed sMDD (0.2). This suggests BD1 cases may function in a similar manner to 
rMDD cases in meta-analysis with PGC MDD, while BD2 cases appear to be 
equivalent to more extreme rMDD cases. As expected, like-for-like, rMDD cases 
provide more loci than sMDD cases, most likely due to increased heterogeneity of 
sMDD cases (potentially because single depressive episodes may be more likely to 
represent a reaction to a specific event). This fits with the higher heritability of 
recurrent major depressive disorder (45%) versus single episode major depressive 
disorder (34%) (58). These conclusions mirror the increase in mean-chi-square of 
each meta-analysis compared to PGC MDD alone (Supplementary Table 20). 
However, limitations remain, including the unknown effects of error (such that it is 
difficult to assess the meaning of differences between subtypes robustly) and the 
fact that the major depressive disorder subtypes are drawn from the same source 
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(UK Biobank), which may differ from clinically-ascertained major depressive disorder 
cohorts, both in heterogeneity and in severity (4, 59). 
Associations of polygenic risk scores for PGC BD with UKB MDD subtypes 
Polygenic risk scores derived from the PGC BD analysis (Supplementary 
Table 21, Supplementary Figure 41) were significantly positively associated with 
rMDD when compared to sMDD (p = 3x10-16; empirical p = 5x10-5) and when 
compared to subMDD (p = 3x10-19; empirical p = 5x10-5). In contrast, the association 
between the PGC BD risk score and sMDD compared to subMDD was not significant 
when taking into account the multiple thresholds tested (p = 0.04; empirical p = 
0.13). Grouping rMDD and sMDD together as UKB MDD cases, the PGC BD risk 
score was significantly positively associated with UKB MDD cases compared to 
controls (p = 6x10-40; empirical p = 5x10-5). Taken together, these results suggest 
that rMDD has more in common genetically with PGC BD than does sMDD. This 
mirrors previous findings that showed BD2 was more similar genetically to PGC 
MDD than was BD1 (16). 
Relationship of meta-analysis results (hierarchical clustering) 
Hierarchical clustering of the significant loci from MOOD and combined MDD 
with the same loci from PGC MDD, UKB MDD, and PGC BD (and the PGC2 SCZ for 
comparison) (22) resulted in MOOD clustering most closely with PGC MDD. This 
indicates that the primary contribution to significant loci in the meta-analysis came 
from PGC MDD rather than PGC BD (Supplementary Figure 42). Results from UKB 
MDD for these loci clustered closer to PGC BD than to PGC MDD, suggesting that 
the component analyses cluster primarily by their contribution to the meta-analysis, 
rather than by trait. Despite this similarity between UKB MDD and PGC BD when 
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considering genome-wide significant loci, comparisons of the SNP-heritability of the 
component analyses (Supplementary Table 2) and of the genetic correlations 
between them (Supplementary Table 10) confirm that UKB MDD is more similar in 
general to PGC MDD than to PGC BD. 
Sensitivity analysis - Equivalently-powered cohorts 
Summary statistics were available from the PGC comprising the PGC MDD 
cohort without the inclusion of the 23andMe and the original UK Biobank cohorts. 
The mean chi-square of the meta-analysis between the down-sampled PGC MDD 
and UKB MDD was 1.35 (compared to 1.70 in combined MDD), similar to the mean 
chi-square of PGC BD and therefore suitable for the purpose of the sensitivity 
analysis (Supplementary Table 2). We therefore meta-analysed down-sampled PGC 
MDD, PGC BD and UKB MDD (down-sampled MOOD; cases = 95,418, controls = 
192,514, non-overlapping N = 280,214).  
19 loci reached genome-wide significance, of which 17 were present in 
MOOD and two did not reach significance in any of the main analyses 
(Supplementary Table 3). Hierarchical clustering of the significant loci from down-
sampled MOOD with the same loci from down-sampled PGC MDD, UKB MDD, and 
PGC BD (and the PGC2 SCZ for comparison) (22) resulted in all three component 
analysis clustering together, with the meta-analysis clustering separately 
(Supplementary Figure 43). This suggests that the clustering of PGC MDD with 
MOOD in the main paper resulted from the power difference. UKB MDD again 
clustered more closely with PGC BD than with down-sampled PGC MDD, although 
the genetic correlation of UKB MDD with down-sampled PGC MDD (rg = 0.86) was 
still greater than with PGC BD (rg = 0.34). 
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Nine of the 44 PGC MDD loci reached genome-wide significance in the down-
sampled MOOD meta-analysis (20% of all PGC MDD loci), as did both of the loci 
that reached genome-wide significance in down-sampled PGC MDD (Supplementary 
Table 3). In comparison, only two of the 19 PGC BD loci reached genome-wide 
significance in the meta-analysis (11%), suggesting that the addition of individuals 
with bipolar disorder to major depressive disorder cohorts still appears to enrich 
more for associations with major depressive disorder than for bipolar disorder.  
Two loci reaching genome-wide significance in down-sampled MOOD did not 
reach genome-wide significance in MOOD, of which one reached significance in 
PGC BD. The other is a multi-gene locus on chromosome 3 that has reached 
genome-wide significance in a wide variety of traits, including depressive symptoms 
(60). In addition to this locus, a further seven loci reached genome-wide significance 
in down-sampled MOOD that did not reach significance in PGC MDD or PGC BD 
including locus 30, near PCLO (but not locus 51, near DRD2). 
The estimate of SNP-heritability for down-sampled MOOD (11% with 
population prevalence 16%) was greater than that for MOOD (8.8%), but still 
remains more similar to PGC MDD (9%) than to PGC BD (17-23%; Supplementary 
Table 2) (1, 16). Similarly, the genetic correlations between down-sampled MOOD 
and other traits broadly recapitulated those for MOOD (Supplementary Table 5). 
Significantly greater correlations (compared with MOOD) were seen between down-
sampled MOOD and bipolar disorder, schizophrenia, combined analyses of bipolar 
disorder and schizophrenia, and the cross-disorder analysis, while reduced 
correlations were seen with PGC MDD and anxiety (Supplementary Table 7). 
Interestingly, a significant negative correlation with IQ was observed (rg = -0.13, p = 
5x10-7), which was not observed in MOOD, PGC MDD nor PGC BD. Further 
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investigation of this genetic correlation revealed that the 23andMe depression cohort 
has a positive genetic correlation with IQ (rg = 0.06, p = 0.01); including this cohort in 
the PGC MDD sample obscured a negative genetic correlation with IQ. 
Overall, the sensitivity analyses suggest that the difference in power between 
combined MDD and PGC BD does contribute to the greater similarity of MOOD to 
PGC MDD than to PGC BD. However, the pervasive similarity to PGC MDD seen in 
the down-sampled analysis suggests the results seen in the main analysis are not 
just a consequence of the power difference. 
The observed SNP-based heritability of down-sampled MOOD from HESS 
was 11% (compare LDSC 8%; Supplementary Tables 2 and 18). Only one region, 
part of locus 25, had local SNP-based heritability significantly >0 in down-sampled 
MOOD. One novel region on chromosome 10 had local SNP-based heritability 
significantly >0 in down-sampled MDD (and in the down-sampled PGC MDD) – 
however, no significant variants were observed in this region, so this may be 
spurious. Down-sampled MDD and PGC BD were significantly genetically correlated 
(0.33, compare 0.37 from LDSC), but no regions had local genetic covariance that 
significantly differed from 0 (all p > 2.94x10-5; Supplementary Table 19). 
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Supplementary Figures  
Supplementary Figure 1 
 
 
 
Supplementary Figure 1: Manhattan and QQ plot of results for the mood disorders (MOOD) 
meta-analysis. Red line is 5x10-8 
 
Supplementary Figure 2 
 
 
 
Supplementary Figure 2: Manhattan and QQ plot of results for the combined MDD meta-
analysis. Red line is 5x10-8 
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Supplementary Figure 3 
 
 
 
Supplementary Figure 3: Manhattan and QQ plot of results for the MDD-BD1 meta-analysis. 
Red line is 5x10-8 
 
Supplementary Figure 4 
 
 
 
Supplementary Figure 4: Manhattan and QQ plot of results for the MDD-BD2 meta-analysis. 
Red line is 5x10-8 
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Supplementary Figure 5 
 
 
 
Supplementary Figure 5: Manhattan and QQ plot of results for the MDD-SAB meta-analysis. 
Red line is 5x10-8 
 
Supplementary Figure 6 
 
 
 
Supplementary Figure 6: Manhattan and QQ plot of results for the MDD-rMDD meta-
analysis. Red line is 5x10-8 
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Supplementary Figure 7 
 
 
 
Supplementary Figure 7: Manhattan and QQ plot of results for the MDD-sMDD meta-
analysis. Red line is 5x10-8 
 
Supplementary Figure 8 
 
 
 
Supplementary Figure 8: Manhattan and QQ plot of results for the MDD-subMDD meta-
analysis. Red line is 5x10-8 
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Supplementary Figure 9 
 
 
Supplementary Figure 9: Hierarchical clustering of the genetic correlations between major 
depression subtypes from UK Biobank (rMDD, sMDD, subMDD) and bipolar disorder 
subtypes (BD1, BD2, SAB). Blue = positive genetic correlation. Red = negative genetic 
correlation. Full genetic correlation results are provided in Supplementary Table 4. 
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Supplementary Figure 10 
 
 
Supplementary Figure 10: Hierarchical clustering of the genetic correlations between major 
depression subtypes from UK Biobank (rMDD, sMDD, subMDD) and bipolar disorder 
subtypes (BD1, BD2, SAB), in the context of genetic correlations with external traits 
(schizophrenia, anxiety disorders, attention deficit hyperactivity disorder, the wellbeing 
spectrum, hedonic wellbeing and eudaimonic wellbeing). Genetic correlations with the 
wellbeing spectrum are reversed, such that they are correlations with low wellbeing.  
Blue = positive genetic correlation. Red = negative genetic correlation. Full genetic 
correlation results are provided in Supplementary Table 4 and Supplementary Table 7 (for 
external traits).   
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Supplementary Figure 11 
 
 
 
Supplementary Figure 11: Cell-type expression specificity of genes associated with bipolar 
disorder (PGC BD, left) and the down-sampled major depressive disorder GWAS (down-
sampled MDD, right). Black vertical lines = significant enrichment (p < 2x10-3, Bonferroni 
correction for 24 cell types). See Supplementary Table 15 for full results. 
  
Down-sampled major 
depressive disorderBipolar disorder
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Supplementary Figure 12 
 
a)  
 
 
Supplementary Figure 12a: Selected genetic correlations of psychiatric traits with the main 
and conditional analyses of MDD (combined MDD, MDDcBD), and bipolar disorder (PGC BD 
and BDcMDD). Full genetic correlation results are provided in Supplementary Table 5. 
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Supplementary Figure 12 (continued) 
 
b) 
 
 
Supplementary Figure 12b: Selected genetic correlations of other traits with the main and 
conditional analyses of MDD (combined MDD, MDDcBD), and bipolar disorder (PGC BD and 
BDcMDD). Full genetic correlation results are provided in Supplementary Table 5. 
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Supplementary Figure 13 
  
 
Supplementary Figure 13: GSMR results from analyses with the main meta-analysis 
(MOOD), the main and conditional MDD (combined MDD, MDDcBD) and bipolar disorder 
(PGC BD, BDcMDD) analyses. External traits are coronary artery disease (CAD), 
educational attainment (EDU), body mass index (BMI), and schizophrenia (SCZ).  
* p < 0.004 (Bonferroni correction for two-way comparisons with six external traits). For 
figure data, including the number of non-pleiotropic SNPs included in each instrument, see 
Supplementary Table 12.  
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Supplementary Figure 14 
 
 
 
 
Supplementary Figure 14: Circos plot of significant loci from mood disorders (MOOD) on 
chromosome 1. Outer circle: Plot of individual variants in each locus, coloured by LD to 
labelled index variant (r2 0.8 -> 1, orange -> red). Middle ring: position of locus on 
chromosome, loci shown in blue. Inner ring: Links between loci and nearby genes, by eQTLs 
(green), chromatin contacts (orange) or both (red)  
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Supplementary Figure 15 
 
 
 
Supplementary Figure 15: Circos plot of significant loci from mood disorders (MOOD) on 
chromosome 2. Outer circle: Plot of individual variants in each locus, coloured by LD to 
labelled index variant (r2 0.8 -> 1, orange -> red). Middle ring: position of locus on 
chromosome, loci shown in blue. Inner ring: Links between loci and nearby genes, by eQTLs 
(green), chromatin contacts (orange) or both (red)  
Coleman et al.  Supplement 
 
61 
Supplementary Figure 16 
 
 
 
Supplementary Figure 16: Circos plot of significant loci from mood disorders (MOOD) on 
chromosome 3. Outer circle: Plot of individual variants in each locus, coloured by LD to 
labelled index variant (r2 0.8 -> 1, orange -> red). Middle ring: position of locus on 
chromosome, loci shown in blue. Inner ring: Links between loci and nearby genes, by eQTLs 
(green), chromatin contacts (orange) or both (red)  
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Supplementary Figure 17 
 
 
 
Supplementary Figure 17: Circos plot of significant loci from mood disorders (MOOD) on 
chromosome 4. Outer circle: Plot of individual variants in each locus, coloured by LD to 
labelled index variant (r2 0.8 -> 1, orange -> red). Middle ring: position of locus on 
chromosome, loci shown in blue. Inner ring: Links between loci and nearby genes, by eQTLs 
(green), chromatin contacts (orange) or both (red)  
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Supplementary Figure 18 
 
 
 
Supplementary Figure 18: Circos plot of significant loci from mood disorders (MOOD) on 
chromosome 5. Outer circle: Plot of individual variants in each locus, coloured by LD to 
labelled index variant (r2 0.8 -> 1, orange -> red). Middle ring: position of locus on 
chromosome, loci shown in blue. Inner ring: Links between loci and nearby genes, by eQTLs 
(green), chromatin contacts (orange) or both (red)  
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Supplementary Figure 19 
 
 
Supplementary Figure 19: Circos plot of significant loci from mood disorders (MOOD) on 
chromosome 6. Outer circle: Plot of individual variants in each locus, coloured by LD to 
labelled index variant (r2 0.8 -> 1, orange -> red). Middle ring: position of locus on 
chromosome, loci shown in blue. Inner ring: Links between loci and nearby genes, by eQTLs 
(green), chromatin contacts (orange) or both (red)  
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Supplementary Figure 20 
 
 
 
Supplementary Figure 20: Circos plot of significant loci from mood disorders (MOOD) on 
chromosome 7. Outer circle: Plot of individual variants in each locus, coloured by LD to 
labelled index variant (r2 0.8 -> 1, orange -> red). Middle ring: position of locus on 
chromosome, loci shown in blue. Inner ring: Links between loci and nearby genes, by eQTLs 
(green), chromatin contacts (orange) or both (red)  
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Supplementary Figure 21 
 
 
 
Supplementary Figure 21: Circos plot of significant loci from mood disorders (MOOD) on 
chromosome 9 (Note – there are no significant loci present on chromosome 8, so no circos 
plot is required). Outer circle: Plot of individual variants in each locus, coloured by LD to 
labelled index variant (r2 0.8 -> 1, orange -> red). Middle ring: position of locus on 
chromosome, loci shown in blue. Inner ring: Links between loci and nearby genes, by eQTLs 
(green), chromatin contacts (orange) or both (red)  
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Supplementary Figure 22 
 
 
 
Supplementary Figure 22: Circos plot of significant loci from mood disorders (MOOD) on 
chromosome 10. Outer circle: Plot of individual variants in each locus, coloured by LD to 
labelled index variant (r2 0.8 -> 1, orange -> red). Middle ring: position of locus on 
chromosome, loci shown in blue. Inner ring: Links between loci and nearby genes, by eQTLs 
(green), chromatin contacts (orange) or both (red)  
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Supplementary Figure 23 
 
 
 
Supplementary Figure 23: Circos plot of significant loci from mood disorders (MOOD) on 
chromosome 11. Outer circle: Plot of individual variants in each locus, coloured by LD to 
labelled index variant (r2 0.8 -> 1, orange -> red). Middle ring: position of locus on 
chromosome, loci shown in blue. Inner ring: Links between loci and nearby genes, by eQTLs 
(green), chromatin contacts (orange) or both (red)  
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Supplementary Figure 24 
 
 
 
Supplementary Figure 24: Circos plot of significant loci from mood disorders (MOOD) on 
chromosome 12. Outer circle: Plot of individual variants in each locus, coloured by LD to 
labelled index variant (r2 0.8 -> 1, orange -> red). Middle ring: position of locus on 
chromosome, loci shown in blue. Inner ring: Links between loci and nearby genes, by eQTLs 
(green), chromatin contacts (orange) or both (red) 
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Supplementary Figure 25 
 
 
 
Supplementary Figure 25: Circos plot of significant loci from mood disorders (MOOD) on 
chromosome 13. Outer circle: Plot of individual variants in each locus, coloured by LD to 
labelled index variant (r2 0.8 -> 1, orange -> red). Middle ring: position of locus on 
chromosome, loci shown in blue. Inner ring: Links between loci and nearby genes, by eQTLs 
(green), chromatin contacts (orange) or both (red)  
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Supplementary Figure 26 
 
 
 
Supplementary Figure 26: Circos plot of significant loci from mood disorders (MOOD) on 
chromosome 14. Outer circle: Plot of individual variants in each locus, coloured by LD to 
labelled index variant (r2 0.8 -> 1, orange -> red). Middle ring: position of locus on 
chromosome, loci shown in blue. Inner ring: Links between loci and nearby genes, by eQTLs 
(green), chromatin contacts (orange) or both (red)  
Coleman et al.  Supplement 
 
72 
Supplementary Figure 27 
 
 
 
Supplementary Figure 27: Circos plot of significant loci from mood disorders (MOOD) on 
chromosome 15. Outer circle: Plot of individual variants in each locus, coloured by LD to 
labelled index variant (r2 0.8 -> 1, orange -> red). Middle ring: position of locus on 
chromosome, loci shown in blue. Inner ring: Links between loci and nearby genes, by eQTLs 
(green), chromatin contacts (orange) or both (red)  
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Supplementary Figure 28 
 
 
 
Supplementary Figure 28: Circos plot of significant loci from mood disorders (MOOD) on 
chromosome 16. Outer circle: Plot of individual variants in each locus, coloured by LD to 
labelled index variant (r2 0.8 -> 1, orange -> red). Middle ring: position of locus on 
chromosome, loci shown in blue. Inner ring: Links between loci and nearby genes, by eQTLs 
(green), chromatin contacts (orange) or both (red)  
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Supplementary Figure 29 
 
 
 
Supplementary Figure 29: Circos plot of significant loci from mood disorders (MOOD) on 
chromosome 17. Outer circle: Plot of individual variants in each locus, coloured by LD to 
labelled index variant (r2 0.8 -> 1, orange -> red). Middle ring: position of locus on 
chromosome, loci shown in blue. Inner ring: Links between loci and nearby genes, by eQTLs 
(green), chromatin contacts (orange) or both (red)  
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Supplementary Figure 30 
 
 
 
Supplementary Figure 30: Circos plot of significant loci from mood disorders (MOOD) on 
chromosome 18. Outer circle: Plot of individual variants in each locus, coloured by LD to 
labelled index variant (r2 0.8 -> 1, orange -> red). Middle ring: position of locus on 
chromosome, loci shown in blue. Inner ring: Links between loci and nearby genes, by eQTLs 
(green), chromatin contacts (orange) or both (red)  
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Supplementary Figure 31: Circos plot of significant loci from mood disorders (MOOD) on 
chromosome 19. Outer circle: Plot of individual variants in each locus, coloured by LD to 
labelled index variant (r2 0.8 -> 1, orange -> red). Middle ring: position of locus on 
chromosome, loci shown in blue. Inner ring: Links between loci and nearby genes, by eQTLs 
(green), chromatin contacts (orange) or both (red)  
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Supplementary Figure 32 
 
 
 
 
Supplementary Figure 32: Circos plot of significant loci from mood disorders (MOOD) on 
chromosome 20. Outer circle: Plot of individual variants in each locus, coloured by LD to 
labelled index variant (r2 0.8 -> 1, orange -> red). Middle ring: position of locus on 
chromosome, loci shown in blue. Inner ring: Links between loci and nearby genes, by eQTLs 
(green), chromatin contacts (orange) or both (red)  
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Supplementary Figure 33: Circos plot of significant loci from mood disorders (MOOD) on 
chromosome 22 (Note – there are no significant loci present on chromosome 21, so no 
circos plot is required). Outer circle: Plot of individual variants in each locus, coloured by LD 
to labelled index variant (r2 0.8 -> 1, orange -> red). Middle ring: position of locus on 
chromosome, loci shown in blue. Inner ring: Links between loci and nearby genes, by eQTLs 
(green), chromatin contacts (orange) or both (red)  
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Supplementary Figure 34 
 
 
 
 
Supplementary Figure 34: Genetic correlations across the mood disorder spectrum, with all 
paths. Arrows labels show genetic correlations. Solid arrows represent genetic correlations 
significantly different from 0 and not significantly different from 1.  
Dotted arrows represent genetic correlations significantly different from 0 and from 1.  
Dashed arrows represent genetic correlations not significantly different from 0.  
Significance in both cases means p < 0.00333 (Bonferroni correction for 15 tests). 
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Supplementary Figure 35 
 
 
 
 
Supplementary Figure 35: Genetic correlations across the mood disorder spectrum with all 
paths (as Supplementary Figure 34), in the context of genetic correlations with 
schizophrenia. Arrows labels show genetic correlations. Solid arrows represent genetic 
correlations significantly different from 0 and not significantly different from 1.  
Dotted arrows represent genetic correlations significantly different from 0 and from 1.  
Dashed arrows represent genetic correlations not significantly different from 0.  
For consistency with Supplementary Figure 31, significance in both cases means p < 
0.00333 (Bonferroni correction for 15 tests).  
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Supplementary Figure 36 
 
 
 
 
Supplementary Figure 36: Genetic correlations across the mood disorder spectrum with all 
paths (as Supplementary Figure 34), in the context of genetic correlations with anxiety. 
Arrows labels show genetic correlations. Solid arrows represent genetic correlations 
significantly different from 0 and not significantly different from 1.  
Dotted arrows represent genetic correlations significantly different from 0 and from 1.  
Dashed arrows represent genetic correlations not significantly different from 0.  
For consistency with Supplementary Figure 31, significance in both cases means p < 
0.00333 (Bonferroni correction for 15 tests).  
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Supplementary Figure 37 
 
 
 
 
Supplementary Figure 37: Genetic correlations across the mood disorder spectrum with all 
paths (as Supplementary Figure 34), in the context of genetic correlations with ADHD. 
Arrows labels show genetic correlations. Solid arrows represent genetic correlations 
significantly different from 0 and not significantly different from 1.  
Dotted arrows represent genetic correlations significantly different from 0 and from 1.  
Dashed arrows represent genetic correlations not significantly different from 0.  
For consistency with Supplementary Figure 31, significance in both cases means p < 
0.00333 (Bonferroni correction for 15 tests).  
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Supplementary Figure 38 
 
 
 
 
Supplementary Figure 38: Genetic correlations across the mood disorder spectrum with all 
paths (as Supplementary Figure 34), in the context of genetic correlations with the well-being 
spectrum. Arrows labels show genetic correlations. Solid arrows represent genetic 
correlations significantly different from 0 and not significantly different from 1.  
Dotted arrows represent genetic correlations significantly different from 0 and from 1.  
Dashed arrows represent genetic correlations not significantly different from 0.  
For consistency with Supplementary Figure 31, significance in both cases means p < 
0.00333 (Bonferroni correction for 15 tests).  
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Supplementary Figure 39: Genetic correlations across the mood disorder spectrum with all 
paths (as Supplementary Figure 34), in the context of genetic correlations with hedonic well-
being. Arrows labels show genetic correlations. Solid arrows represent genetic correlations 
significantly different from 0 and not significantly different from 1.  
Dotted arrows represent genetic correlations significantly different from 0 and from 1.  
Dashed arrows represent genetic correlations not significantly different from 0.  
For consistency with Supplementary Figure 31, significance in both cases means p < 
0.00333 (Bonferroni correction for 15 tests).  
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Supplementary Figure 40 
 
 
 
 
Supplementary Figure 40: Genetic correlations across the mood disorder spectrum with all 
paths (as Supplementary Figure 34), in the context of genetic correlations with eudaimonic 
well-being. Arrows labels show genetic correlations. Solid arrows represent genetic 
correlations significantly different from 0 and not significantly different from 1.  
Dotted arrows represent genetic correlations significantly different from 0 and from 1.  
Dashed arrows represent genetic correlations not significantly different from 0.  
For consistency with Supplementary Figure 31, significance in both cases means p < 
0.00333 (Bonferroni correction for 15 tests).  
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Supplementary Figure 41 
 
Supplementary Figure 41: Three-dimensional scatterplot of the first three principal 
components of the genetic correlation matrix of the mood disorder subtypes (green labels) 
with six external GWAS (orange labels). Principal component (PC) 1 separates BD1, SAB 
and schizophrenia from the depressive disorders, with BD2 and ADHD intermediate. PC2 
separates eudaimonic and hedonic wellbeing from the other phenotypes. PC3 separates 
ADHD from the other phenotypes.  
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Supplementary Figure 42 
 
 
 
Supplementary Figure 42: Distribution of polygenic risk scores derived from PGC BD 
(pThresh = 0.2) in individuals with recurrent major depressive disorder (rMDD cases), single 
episode major depressive disorder (sMDD cases), subthreshold depression (subMDD 
pseudo-cases) and controls. Black bars - significant differences in means (empirical p < 
0.05)  
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Supplementary Figure 43: Hierarchical clustering of the significant loci from the mood 
disorders meta-analysis (MOOD) with the same loci from PGC MDD, UKB MDD, PGC BD, 
and SCZ. Blue = positive direction of effect. Red = negative direction of effect. 
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Supplementary Figure 44 
 
 
 
Supplementary Figure 44: Hierarchical clustering of the significant loci from the down-
sampled mood disorders meta-analysis (down-sampled MOOD) with the same loci from 
down-sampled PGC MDD, UKB MDD, PGC BD, and SCZ. Blue = positive direction of effect. 
Red = negative direction of effect. 
